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ROLE OF OXIDATIVE MODIFICATIONS OF LKB1 IN PROMOTING 
MYOCARDIAL HYPERTROPHY 
TIMOTHY DEAN CALAMARAS 
Boston University School of Medicine, 2014 
Major Professor: Wilson S. Colucci, M.D., Professor of Medicine 
ABSTRACT 
The pathogenesis of heart failure (HF) involves compensatory left 
ventricular hypertrophy. Reactive oxygen species (ROS) are elevated in HF and 
mediate myocardial hypertrophy. ROS also mediate formation of lipid 
peroxidation byproducts, yet little is known about their role in promoting 
hypertrophy. One lipid peroxidation byproduct, 4-hydroxy-trans-2-nonenal (HNE) 
is a reactive aldehyde that forms covalent adducts on proteins. HNE levels are 
also elevated in HF and may mediate hypertrophy via HNE-adduct formation. 
LKB1 – a tumor suppressor protein – regulates cellular growth through activation 
of the downstream kinase AMPK. Activation of AMPK suppresses functions that 
consume ATP and simultaneously activates processes to generate energy. The 
LKB1 protein is inhibited by oxidants, but whether this results in myocardial 
hypertrophy is unclear. I hypothesized that HNE can directly promote cardiac 
hypertrophy via the modification of LKB1. 
 In HEK293T cells I observed that HNE adducts inhibit activity of LKB1 
through direct oxidative modification. Mutation of LKB1 Lys-96 or Lys-97 resulted 
in less HNE-LKB1 adduct formation. Mutation of LKB1 Lys-97 prevented the 
 xii 
inhibitory effect of HNE, suggesting that HNE-adduction at this residue is 
sufficient to inhibit LKB1. In cardiomyocytes HNE inhibited both LKB1 and AMPK, 
increased phosphorylation of mTOR, p70S6K, and S6K, and increased protein 
synthesis. HNE also activated Erk1/2, which contributed to S6K activation but 
was not required for cellular growth. Hypertrophic S6K activation was dependent 
on mTOR. Mice fed a high-fat high-sucrose (HFHS) diet have myocardial 
hypertrophy that can be prevented by antioxidants. Hearts of HFHS mice have 
HNE-LKB1 adducts, inhibited LKB1 activity, yet no change in AMPK activation. 
Mice lacking aldehyde dehydrogenase 2 (ALDH2), an enzyme involved in HNE 
detoxification, have increased myocardial hypertrophy when fed HFHS diet yet 
have increased LKB1 activity. 
 In summary HNE directly causes hypertrophy in cardiomyocytes. This 
occurs through inhibition of LKB1 and in part through Erk1/2 activation. In HFHS-
fed mice HNE-LKB1 adduct formation is associated with decreased LKB1 
activity. Impairing detoxification of reactive aldehydes in the ALDH2-KO mice is 
sufficient to increase myocardial hypertrophy, but this appears to be independent 
of LKB1. This study demonstrates a novel mechanism of cardiac hypertrophy 
caused by reactive aldehydes. 
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Chapter 1. Introduction 
 
1.1 Heart failure with preserved ejection fraction 
According to the latest data from the Centers for Disease Control, 
currently 5.1 million people in the United States have been diagnosed with heart 
failure (HF) and about half of those diagnosed will die within 5 years (1). The 
monetary cost of HF in terms of health care related services, medications, and 
time spent ill are estimated at $32 billion each year (2). The scope of this disease 
in regards to both loss of life and financial impact demands scientific investigation 
to generate novel approaches in the treatment of HF and management of 
symptoms. 
HF is the progressive deterioration of the heart’s ability to circulate blood 
to peripheral tissues. In an attempt to maintain cardiac output the structure of the 
heart adaptively remodels, yet over time this initial response can lead to dilation 
of the ventricle and an inability to provide adequate cardiac output, resulting in 
contractile dysfunction termed systolic HF (3). In other HF patients the heart has 
no contractile dysfunction, but during diastole the left ventricle is unable to 
properly refill with blood. This syndrome was originally described as diastolic 
heart failure (4) but is now more accurately labeled HF with preserved ejection 
fraction (5). It has been observed that about one half of patients admitted to the 
hospital with symptoms of HF have preserved ejection fraction (6,7). Patients 
enrolled in the Framingham Study had equivalent cardiovascular outcomes 
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regardless of ejection fraction status (8), indicating that HF with preserved 
ejection fraction is a significant clinical phenotype. It should be noted that HF 
patients with systolic dysfunction have a number of pharmacological 
interventions available to address underlying cardiovascular pathology 
(angiotensin-converting-enzyme inhibitors, beta-adrenoceptor blockers) but for 
patients suffering from HF with preserved ejection fraction the standard of care is 
limited to alleviating symptoms with diuretics or vasodilators (9), indicating a 
need for therapeutics in this half of HF patients. In addition to impaired ventricular 
relaxation observed in HF with preserved ejection fraction, a predominant clinical 
manifestation is concentric cardiac hypertrophy that occurs as part of the 
remodeling process (10). Myocardial hypertrophy has been used to predict HF in 
patients without prior myocardial infarction (11), and patients with concentric left 
ventricular hypertrophy are more likely to develop HF with preserved ejection 
fraction (12). 
Obesity has been recently identified as a risk factor for HF and has been 
associated with both systolic and diastolic dysfunction (13). Patients with a 
preserved ejection fraction had worsening diastolic function and myocardial 
hypertrophy with higher body mass index (BMI), independent of other risk factors 
(14). Diabetes is another well-established risk factor for HF that was validated by 
the Framingham Heart Study in 1974 (15). Patients with increased insulin 
resistance were observed to have advanced HF (16) and insulin resistance 
predicts risk of HF independently of other risk factors (17). Currently over 2/3 of 
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Americans are overweight and 1/6 of the population has been diagnosed with 
metabolic syndrome (18). Based on these numbers, the potential impact of 
obesity and diabetes on cardiovascular outcomes is a significant public health 
concern that necessitates scientific investigation into avenues for therapeutic 
intervention. 
In the setting of diabetes and insulin resistance increased circulating free 
fatty acids can overwhelm the capacity of fatty acid oxidation, resulting in ectopic 
lipid accumulation in non-adipose tissue including the heart, liver, and pancreas 
(19). Excess lipids interfere with normal cell function in these organs and can 
result in lipotoxic cellular dysfunction, yet the precise molecular mechanisms of 
lipid-induced cellular dysfunction have not been fully elucidated. Lipid 
accumulation within the heart has been linked to impaired cardiac contractility in 
obese rodents (20,21) and reduction of cardiac lipid content in the obese rat 
improved cardiac function, suggesting a role for lipids in the pathogenesis of 
heart failure. Myocardial triglyceride content in humans predicts diastolic function 
independently of BMI, blood pressure, and biochemical blood markers (22), 
further implicating lipid accumulation in the pathogenesis of heart failure. 
 
1.2 Role of ROS in promoting myocardial hypertrophy in animal models of 
HF.  
The healthy adult heart derives 50-75% of its ATP under normal 
conditions from fatty acid oxidation (23). In animal models of obesity and 
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diabetes the heart increases oxidation of fatty acids and myocardial oxygen 
consumption, resulting in decreased mitochondrial efficiency (24) and increased 
production of reactive oxygen species (ROS) (25). In the cardiovascular system 
low levels of ROS are thought to act as potent signaling mediators yet at higher 
concentrations interfere with normal cellular function, a topic we have recently 
reviewed (26). 
During HF, stimulation of the adrenergic system releases catecholamines 
such as norepinephrine, epinephrine, and dopamine in response to contractile 
dysfunction as a way to increase cardiac output (27). In cultured cardiomyocytes, 
stimulation of α-adrenergic receptors (AR) with norepinephrine promotes 
myocardial hypertrophy and is used as a model system for catecholamine-
induced myocardial remodeling (28). Using cultured adult rat ventricular 
myocytes (ARVMs) our lab (29) and others (30) have shown that α-AR 
stimulation induces cellular hypertrophy through activation of canonical Mitogen 
Activated Protein Kinase (MAPK) signaling: p21Ras-Rapidly Accelerated 
Fibrosarcoma (Raf)-Mitogen-activated Erk kinase (MEK) 1/2-Extracellular 
signaling-regulated kinases (Erk) 1/2. Hypertrophy induced by α-AR activation is 
dependent on ROS formation (31) and treatment of cardiomyocytes directly with 
oxidants causes myocyte hypertrophy via the MAPK pathway (32). Furthermore 
α-AR stimulated hypertrophy involves oxidative modification of reactive thiols on 
the p21Ras protein that increase kinase activity and potentiate MAPK signaling 
(33). 
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In a mouse model of systolic HF caused by cardiomyocyte-specific Gαq 
transgene expression we have shown that cardiomyocyte-specific transgenic 
expression of the antioxidant catalase decreases myocardial hypertrophy and 
ameliorates cardiac function (34). Others have shown that a transgene for 
mitochondrially-targeted catalase prevents deleterious cardiac remodeling when 
overexpressed in the Gαq mice and in mice administered the hypertrophic agent 
Angiotensin II (35). Furthermore, the mitochondrial-targeted antioxidant peptide 
SS-31 partially rescued the cardiac phenotype of Gαq overexpressing mice when 
administered for 4 weeks (36). Mice with heart/skeletal muscle loss of the 
mitochondrial antioxidant enzyme manganese superoxide dismutase (MnSOD) 
exhibited a spontaneous and severe systolic HF phenotype within 2 months (37). 
When MnSOD deficient mice were administered the antioxidant compound 
manganese 5,10,15,20-tetrakis (4-benzoic acid) porphyrin (MnTBAP) 
intraperitoneally for 4-8 weeks, the deterioration in cardiac function was partially 
prevented and myocardial hypertrophy was decreased, suggesting oxidants are 
involved in the myocardial pathology of these mice. The antioxidant enzyme 
thioredoxin-1 (Trx-1) regulates hypertrophy in the heart. When the endogenous 
activity of this antioxidant was rendered inactive through cardiomyocyte-specific 
overexpression of a dominant negative form of the protein, the hearts 
hypertrophied without any exogenous stressors (38). Furthermore mice with 
transgenic overexpression of cardiac-specific Trx-1 are resistant to cardiac 
hypertrophy induced by aortic banding. Taken together, these data suggest that 
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oxidant species directly promote adverse myocardial remodeling in animal 
models of systolic HF.  
Animal models of HF with preserved ejection fraction have yet to be as 
rigorously evaluated to determine if oxidants promote myocardial remodeling and 
if antioxidants can prevent the HF phenotype. One animal model of HF with 
preserved ejection is the senescent rodent, which has impaired cardiac 
relaxation (39) as well as myocardial hypertrophy (40). In two independent 
studies investigating mechanisms of HF in aged mice, the transgenic 
overexpression of catalase targeted to either the mitochondrial or peroxisomal 
compartments decreases myocardial hypertrophy, improves cardiac relaxation, 
and decreases markers of oxidatively modified proteins (41,42), suggesting ROS 
are involved in the HF phenotype observed in the senescent rodent. 
In order to better elucidate mechanisms of myocardial dysfunction in the 
setting of obesity and diabetes, a more relevant model for HF with preserved 
ejection fraction is the rodent fed a “western style” diet. We’ve recently fed mice a 
high-fat high-sucrose (HFHS) diet containing 35.5% fat and 36.3% carbohydrate 
(primarily sucrose) for 8 months and observed myocardial hypertrophy, impaired 
ventricular relaxation, and preserved ejection fraction (43). When polyphenols 
were co-administered with the HFHS diet, myocardial hypertrophy was 
decreased and relaxation abnormalities were improved. Other groups have 
observed a similar phenotype in mice fed a “western style” diet containing 60% 
fat, 20% carbohydrates, and 20% protein (44) and in animals fed a high-fat high-
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simple carbohydrate diet (35% fat, 35.4% simple carbohydrate, 20% protein) 
(45). A rat model of HF with preserved ejection fraction was developed by 
crossing Dahl salt-sensitive rats with obese Zucker rats, which have a mutation in 
the leptin receptor gene (46). This animal model has salt-sensitive hypertension, 
myocardial hypertrophy and diastolic dysfunction which worsened between 9 and 
13 weeks of age (47). Caloric restriction decreased cardiac hypertrophy and 
diastolic dysfunction in these mice, an effect that was associated with decreased 
levels of oxidative stress (48). These data suggest that ROS play a role in 
promoting myocardial hypertrophy in HF with preserved ejection fraction, 
potentially through the oxidative post-translational modification of key signaling 
proteins. 
 
1.3 Overview of HNE: methods to detect HNE adducts, and the observed 
effects of HNE 
HNE, perhaps the most studied α,β-unsaturated aldehyde, was first 
observed in peroxidized liver microsomal lipids as the major cytotoxic lipid 
peroxidation byproduct (49) and has since been observed in serum (50), brain 
(51), kidney (52), and the heart (53). The formation of HNE is initiated when free 
radical oxygen species abstract a proton from unsaturated lipid membranes and 
in the process generate lipid peroxyl radicals (54). Decomposition of the lipid 
peroxyl radical species by β-cleavage leads to the generation of reactive short-
chain aldehydes such as malondialdehyde (MDA) and HNE (55). HNE is a highly 
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reactive electrophilic lipid that covalently binds to nucleophilic groups of Cys, Lys, 
and His residues via the Michael reaction or reacts with Lys and Arg to form a 
Schiff base (56). Pathophysiological concentrations of HNE have been reported 
to range from 0.3 µM to 10 µM in local tissues (57,58) and plasma concentrations 
of patients with cerebral ischemia are higher than 10 µM (59). Experiments in 
which exogenous HNE was added to tissue culture models at doses of up to 40 
µM have been shown to result in the formation of HNE-protein adducts and 
alterations in cellular signaling (60-65). Aside from direct protein modification, 
HNE has been shown to induce peroxide formation (66) and mitochondrial-
derived ROS (67), suggesting that the observed effects of HNE exposure may be 
mediated by secondarily generated oxidant species. HNE and other reactive 
aldehydes are elevated in the plasma of HF patients, and increased aldehyde 
levels were associated with impaired left ventricular contractility (68). 
Furthermore, patients with dilated cardiomyopathy exhibited a decrease in 
myocardial HNE-protein modifications when treated with carvedilol, a 
vasodilating β-blocker with antioxidant activity that correlated with an 
amelioration of cardiac function (69). 
An early method used to identify the targets of HNE modification was the 
spectrophotometric detection of a 2,4-dinitrophenol (DNP) derivative that reacts 
with carbonylated proteins (70,71). Other carbonyl reactive probes, such as 
biotin-linked hydrazide (72), allows for identification by mass spectroscopy and 
electrochemical detection of proteins that are oxidatively modified in vitro (73) or 
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in vivo (74,75) . The major limitation of these methods is the non-specificity of 
hydrazide and 2,4-DNP (76) which can react with other aldehydes (i.e. MDA) and 
the possibility that native biotin-containing proteins can be extracted with the 
biotin pulldown (77). Immunochemical detection of HNE-proteins has been used 
with antibodies specific to the histidine and lysine dihydropyrrol HNE-adducts 
(78,79). The antibody specific for HNE-bound histidine has identified cytochrome 
c oxidase modifications in rat heart subjected to ischemia/reperfusion (61) and 
the HNE-lysine antibody has detected modifications of mitochondrial subunits in 
the diabetic rat heart (80). Antibody detection is sufficient to demonstrate the 
presence of HNE, but these antibodies lack specificity and may detect other 
Michael adducts such as 4-hydroxy-2-decenal and 4-hydroxy-2-octenal (79,81). 
To determine endogenous HNE adduct formation enrichment techniques should 
be used with either antibody-bound sepharose (82) or biotin hydrazide to 
selectively isolate Michael adducts (83,84). The problem with each of the latter 
techniques is that both of these compounds react with all carbonyl adducts. 
Other lipid-derived aldehyde species, including carbonyls and acrolein adducts, 
have been identified during cardiovascular disease states and may mediate 
cellular signaling (85). 
In patch-clamp studies, isolated cardiac myocytes perfused with supra-
normal concentrations HNE (400 µM) were shown to undergo membrane 
depolarization and loss of excitability (86). Other work using high concentrations 
on HNE (200 µM) concluded that HNE can induce intracellular calcium overload 
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in cardiomyocytes (87). At 40 µM HNE forms adducts which inhibit the tumor 
suppressor protein liver kinase B 1 (LKB1) to promote signaling changes similar 
to those associated with myocyte hypertrophy (63). At high physiologic levels of 
HNE (10 µM), transient treatment (1-3 hours) increases both oxygen 
consumption and glycolysis while sustained HNE treatment (8-16 hours) greatly 
decreases cell viability (88). At 5 µM, HNE activates the oxidant-sensitive Nrf2 
transcription factor in cardiomyocytes (89) and at 25 µM was shown to increase 
activity of glutamate-cysteine-ligase, the rate limiting enzyme in de-novo GSH 
biosynthesis in A549 human lung adenocarcinoma cells (90). 
Detoxification of free HNE involves oxidation by aldehyde 
dehydrogenases (ALDH), primarily the mitochondrial isoform, ALDH2 (91) or 
reduction by aldose reductase (92). In addition to detoxifying reactive aldehydes 
ALDH2 oxidizes acetaldehyde, a byproduct of ethanol metabolism (93). Among 
Asian populations there is a higher rate of alcohol intolerance as assessed by 
adverse reactions to ethanol ingestion that produces an alcohol-flush reaction. 
The flushing response is caused by excessive acetaldehyde accumulation, and 
has been linked to structural alterations of the ALDH2 protein in the presence of 
preserved ALDH1 activity within the liver (94). An analysis of liver tissue 
demonstrates that ALDH2 protein obtained from alcohol intolerant patients 
contains a glutamine amino acid substituted by lysine (95). Sequencing data from 
liver samples of affected Japanese patients shows that the inactive ALDH2 gene 
results from the mutation of glutamate to lysine at position 487, and that this 
 11 
inactive subunit is dominant (96). Since ALDH2 functions cooperatively as a 
homo- or heterotetramer, all tetramers that contain 1 or more mutated subunits 
are functionally inactive. In a transgenic loss-of-function mouse model, over-
expression of the ALDH2 Lys-487 mutant significantly increased HNE adduction 
of mitochondrial proteins (97). Similarly, aldose reductase deficient mice fed high 
fat diet exhibit increased plasma HNE adducts, advanced glycation endproducts, 
and acrolein formation (98). Interestingly the knockout of aldose reductase had 
no effect on HNE adduct formation in mice fed standard chow diet, suggesting 
that lipid peroxide accumulation may be minimal or otherwise detoxified by 
additional mechanisms under physiological conditions. 
 
1.4 Function and regulation of LKB1 
LKB1, gene name – Serine Threonine Kinase 11 (STK11), is a 
serine/threonine kinase that is now well known for its role in the phosphorylation 
and activation of the AMP-activated protein kinase (AMPK) and 12 other AMPK-
related kinases (99). The gene encoding a homolog of STK11, Xenopus egg and 
embryo kinase (XEEK1), was originally identified in a cDNA library obtained from 
Xenopus ovary extracts as a novel serine/threonine kinase involved in 
embryogenesis (100). XEEK1 was found to be a cytosolic expressed protein that 
may be a potential target of Protein Kinase A and shares 83.7% homology with 
human LKB1. Peutz-Jeghers syndrome (PJS) is an inherited intestinal carcinoma 
primarily characterized by benign intestinal polyp formation (101), yet patients 
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with PJS have an increased risk for other cancers as well (102). Gene linkage 
analysis of patients with PJS have localized gene defects to chromosome 19 
(103) and subsequent investigation by two independent laboratories both 
identified STK11 as the defective gene in PJS (104,105). 
LKB1 functions as a tumor suppressor protein in part by decreasing 
cellular energy availability through regulation of AMPK. AMPK acts as an 
evolutionarily conserved cellular energy gauge that responds to changes in the 
AMP:ATP ratio of the cell directly by binding low energy substrates AMP (106) or 
ADP (107) on the regulatory γ subunit, an interaction which allosterically 
activates the protein. Allosteric activation of AMPK primes the protein for 
phosphorylation of its activation loop (Thr-172) by upstream kinases such as 
LKB1 and Ca2+/calmodulin-dependent protein kinase kinase (CaMKK) which 
increases AMPK activity 100-fold compared to baseline (23,108). Activation of 
AMPK under low energy conditions promotes ATP production while 
simultaneously inhibiting processes that consume energy. In this regard AMPK 
regulates hypertrophy and protein synthesis though the mammalian target of 
rapamycin (mTOR) signaling axis. AMPK indirectly inhibits mTOR, preventing 
both the activation of p70S6 kinase (p70S6K) and the inhibition of 4E-binding 
protein 1(4E-BP1), thereby inhibiting protein synthesis (109).  
Nuclear LKB1 is thought to have limited catalytic activity; translocation to 
the cytosol allows for LKB1 to interact with the pseudokinase STE-related 
adaptor (STRAD) and the scaffold mouse protein 25 (MO25), thus forming a 
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constitutively active heterotrimeric complex (110). Deacetylation of LKB1 at Lys-
48 by silent information regulator 1 (Sirt1) regulates translocation of LKB1 to the 
cytosol (111), and the LKB1-STRAD interaction enhances its cytosolic 
localization (112) (Figure 1). In cultured cardiomyocytes adenoviral 
overexpression of LKB1 and pharmacological activation of AMPK both prevent 
agonist-stimulated cardiac hypertrophy by decreasing protein synthesis 
(113,114). In vivo, the calcineurin transgenic mouse and the spontaneously 
hypertensive rat both exhibit decreased LKB1 protein levels (63,114). One 
mouse model of cardiac myocyte-specific knockout of LKB1 has been created in 
which the floxed LKB1 gene was deleted using Cre under the control of the α-
Myosin Heavy Chain (α-MHC) promoter (115). α-MHC LKB1 deficient hearts 
have biatrial enlargement, left ventricular hypertrophy, pro-hypertrophic 
alterations in AMPK and mTOR/p70S6K signaling, and cardiac dysfunction as 
early as 4 weeks of age. Another model of cardiac LKB1 deficiency was 
generated by deleting the floxed LKB1 gene using the Muscle Creatine Kinase 
(MCK) Cre promoter, causing loss of LKB1 in both the heart and skeletal muscle 
(116). In the MCK-driven model LKB1-deficiency caused no changes in heart 
size, left ventricular wall thickness or fractional shortening. However pro-
hypertrophic signaling changes in AMPK, mTOR, and p70S6K were observed. 
The different cardiovascular phenotypes in these mice may be caused by 
differences in the promoters used in the deletion of the floxed LKB1 gene. The  
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Figure 1. Schematic of LKB1 activation. Deacetylation of LKB1 by Sirt1 primes 
LKB1 for translocation from the nucleus to the cytoplasm. The adaptor protein 
STRAD enhances the translocation of LKB1 and once LKB1 interacts with both 
STRAD and MO25 in the cytoplasm the heterotrimer forms an active complex 
that can phosphorylate downstream targets such as AMPK.  
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MCK promoter may not be as effective at expressing genes in the heart (117), 
which in this model may lead to an incomplete deletion of the floxed LKB1 gene. 
The LKB1 protein is subject to a number of post-translational 
modifications. The most well-studied of these is phosphorylation, which targets at 
least 9 residues of mouse LKB1: Ser-31, Thr-185, Thr-189, Ser-307, Ser-325, 
Thr-336, Thr-366, Ser-399, Ser-404, and Ser-431 (118-120). Of these 
phosphorylation sites the C-terminal Ser-431 has been the most extensively 
studied and is the subject of controversial results. Ser-431 has been shown to be 
phosphorylated by cAMP-dependent protein kinase A (PKA) (121) as well as by 
Erk1/2-mediated p90RSK (122). Mutation of Ser-431 to alanine has revealed that 
phosphorylation of this site is not required for activation of the LKB1 protein, but 
is required to suppress cellular growth in G361 cells (122). An alternative splice 
variant of LKB1 in which the C-terminal end is truncated (termed short form) 
lacks Ser-431, yet forms a complex with STRAD and MO25, and phosphorylates 
and activates AMPK comparable to full length LKB1 (123). When the LKB1 short 
form was expressed in G361 cells, it caused cell cycle arrest and growth 
suppression, suggesting that Ser-431 is not involved in this phenotype (124). A 
study in human umbilical vein endothelial cells has demonstrated that Ser-428 
(equivalent to mouse Ser-431) is required for the activation of AMPK by 
metformin (125). A knock-in mouse expressing homozygous Ser-431 mutations 
to alanine was found to have no phenotype and no change in LKB1 activity or 
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AMPK activation in the liver or muscle (126), further suggesting this residue is 
not required for normal LKB1 function. 
LKB1 is also subject to modification by prenylation (121) and is 
farnesylated at Cys-433 (122). The functional significance of prenylation has also 
yielded contradictory results – initially mutation of this site had no effect on 
decreasing cellular growth of G361 cells (122) and loss of this site in the LKB1 
short form isoform had no effect on AMPK function (123). However knock-in mice 
expressing homozygous mutations of Cys-433 to serine have decreased AMPK 
activity in liver and muscle as well as impaired stimulation of liver AMPK in the 
presence of AICAR (126). The membrane localization of LKB1 in the liver was 
also disrupted in the Cys-433 knock-in mice, and since AMPK has been shown to 
localize to the plasma membrane, it was postulated that disruption of LKB1-
AMPK co-localization may be one mechanism of decreased AMPK activation in 
this tissue. Acetylation of LKB1 Lys residues has also been shown to modulate 
translocation, and this modification is regulated in part by the Sirt1-mediated 
deacetylation (111).  
LKB1 is the target of oxidative-post translational modifications in a variety 
of cellular systems. In MCF-7 cells modification of LKB1 by the reactive lipid 
species HNE, 4-oxo-2-nonenal, and cyclopentenone prostaglandin A and J were 
first observed to impair downstream AMPK phosphorylation (127) (Figure 2). 
Mutation of Cys-210 was sufficient to decrease modification of LKB1, but whether 
this effect restored the activity of AMPK was not evaluated. In neonatal rat  
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Figure 2. Known modifications of the LKB1 protein. The modifications 
included in this figure are phosphorylation (P), hydroxynonenal modification 
(HNE) and farnesylation. Single letter designations represent amino acids 
(S=serine, T=threonine, C=cysteine). 
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cardiomyocytes HNE adducts of LKB1 promote hypertrophic signaling in part 
through AMPK inhibition, and the formation of HNE-LKB1 adducts and 
hypertrophic signaling could be abrogated by pretreatment with the antioxidant 
polyphenol compound resveratrol (63). We have also observed HNE-LKB1 
adducts in hearts from mice with diet-induced obesity which were reversed by co-
administration of a polyphenol compound (43), suggesting that this modification 
may be of importance in regulating hypertrophic growth pathways in vivo. 
 
1.5 Hypothesis  
 Oxidative modification of LKB1 by HNE leads to pro-hypertrophic signaling 
changes under conditions of metabolic stress. 
 
1.6 Specific aims 
1: Test the hypothesis that inhibition of LKB1 by the reactive aldehyde HNE is 
dependent on HNE adduct formation on reactive lysine residues. 
 
2: Test the hypothesis that HNE-induced hypertrophy in cultured adult rat 
ventricular myocytes occurs via both decreased LKB1-AMPK signaling and 
activated Erk signaling. 
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3: Test the hypothesis that “metabolic” myocardial hypertrophy in mice fed high-
fat high-sucrose diet involves HNE-dependent signaling changes through the 
LKB1-AMPK signaling axis. 
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Chapter 2. Materials and Methods 
 
2.1 Reagents 
HNE and MnTMPyP were obtained from Calbiochem and [γ-32P]ATP was 
purchased from PerkinElmer Life Sciences. U0126 was obtained from Cell 
Signaling Technology (CST). Unless noted otherwise, all chemicals were 
provided by Sigma Aldrich.  
2.2 HEK293T cell culture and plasmid expression 
Human embryonic kidney 293T (HEK293T) cells were purchased from 
ATCC (Manassas, VA). The cells were maintained at 37 °C with 5% CO2 and 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) 
supplemented with 25 mM glucose, 110 mg/liter sodium pyruvate, 10% fetal 
bovine serum, and 0.1% penicillin-streptomycin (Invitrogen). The generation of 
the expression constructs for Glutathione S-transferase (GST)-LKB1, His-
STRAD, and FLAG-MO25 and the creation of LKB1 lysine mutations are 
described in full detail by Lan et al (111). HEK293T cells were transiently 
transfected with 0.5 µg of LKB1, STRAD, and MO25 plasmids in each well of a 6-
well plate using the Max-PEI polymer (Polysciences, Inc.). 18 hr post-
transfection, the cells were used for experimentation. 
2.3 ARVM isolation and treatments 
Primary adult rat ventricular myocytes (ARVMs) were isolated from 
Sprague-Dawley rats (175-225 grams) as previously described (128-131). Briefly, 
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the hearts were rapidly excised and perfused with 37 °C Ca2+ free Krebs-
Henseleit Buffer (118 mM NaCl, 4.75 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 
25 mM NaHCO3, pH=7.4) through the aorta using retrograde Langendorff 
perfusion. Next, hearts were digested with recirculating collagenase 
(Worthington) and hyaluronidase (Sigma) for 18-20 min. After the initial digestion 
the heart was cut into small pieces and incubated with the 
collagenase/hyaluronidase enzyme cocktail supplemented with 1 mM CaCl2, 
trypsin, and DNAse at 37 °C for 20-25 minutes with light agitation. The digested 
heart was then filtered through a 100-µm nylon mesh gauze, centrifuged at 500 
rpm for 3 min, and resuspended in wash buffer (1:1 DMEM low gluose: Ca2+ free 
Krebs-Henseleit Buffer). The supernatant containing the non-myocyte fraction of 
cells (smooth muscle cells, endothelial cells, and cardiac fibroblasts) was 
removed and used to isolate cardiac fibroblasts, if necessary. The pellet 
containing the myocyte-enriched population of cells was washed twice with wash 
buffer and allowed to settle for 10 min per wash. Following washing the myocyte 
pellet was gently layered on a Bovine Serum Albumin (BSA) gradient and 
allowed to settle for 15 min. The pellet containing largely viable myocytes was 
resuspended and plated on laminin coated dishes in low glucose “ACCT” media 
(Invitrogen) supplemented with 0.2% BSA, 2 mM Carnitine, 5 mM Creatine, 5 
mM Taurine, 2.5 M Hepes, and 0.1% penicillin-streptomycin for 1 hr to allow for 
myocytes to adhere to the laminin coated plates. The media was then changed 
and the cells were left to incubate overnight prior to experimentation. 
 22 
2.4 Western Blotting Methodology 
 2.4.1 HEK293T cells and ARVMs 
Cells were rinsed with cold PBS and lysed with 1X lysis buffer (CST, 20 
mM Tris-HCl (pH=7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 
2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 
ug/mL leupeptin) supplemented with 1 mM PMSF. The cells were permitted to 
lyse for 30 minutes on ice and afterwards the lysates were cleared by 
centrifugation (13,000 rpm, 10 min, 4 °C). The supernatants were collected, the 
protein content was quantified using the Bradford Reagent (Bio-rad) and proteins 
were diluted in additional lysis buffer and 2X Laemmli sample loading buffer (Bio-
Rad) to a concentration of 1 ug/ul. Protein samples were loaded into precast 
polyacrylamide gels (Bio-Rad) and ran at 200 volts for 40 minutes. The protein 
samples were then transferred to nitrocellulose membranes at 100 volts for 90 
minutes, blocked with blocking buffer (Li-Cor) for 60 minutes at room temperature 
and immuno-blotted with the indicated antibodies (Table 1). Membranes were 
washed in TBS containing 0.1% Tween-20 three times for 5 minutes. Secondary 
antibodies were diluted in blocking buffer at a concentration of 1:20,000 and 
incubated for 60 minutes at room temperature. The probed membranes were 
visualized using the Li-Cor Odyssey IR imager and analyzed by densitometry 
using Odyssey 2.1 software. 
 2.4.2 Whole Heart Tissue Lysates 
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Antibody Supplier Tissue Used Species Dilution 
ACC CST ARVM Rabbit IB: 1:1000 
Akt CST ARVM/mouse heart Rabbit IB: 1:1000 
IP: 1:100 
AMPKα2 Santa Cruz ARVM/mouse heart Goat 
IB: 1:1000 
Erk CST ARVM/mouse heart Mouse IB: 1:1000 
Flag (M2) Sigma HEK293T Mouse IB: 1:1000 
GAPDH Abcam HEK293T/ARVM/mouse heart Mouse IB: 1:10,000 
GST CST HEK293T Rabbit IB: 1:1000 
Histone H3 CST HEK293T Rabbit IB: 1:1000 
HNE Abcam HEK293T Goat IB: 1:1000 
LKB1 D60C5 CST ARVM/mouse heart Rabbit IB: 1:1000 
LKB1 M-18 Santa Cruz ARVM/mouse heart Goat IP: 1:50 
mTOR CST ARVM/mouse heart Mouse IB: 1:1000 
p70S6K CST ARVM Rabbit IB: 1:1000 
p21Ras Millipore ARVM Mouse IB: 1:1000 
STRAD S-17 Santa Cruz HEK293T/ARVM Goat IB: 1:1000 
P-ACC (Ser79) Millipore ARVM/mouse heart Rabbit IB: 1:1000 
P-Akt (Ser473) CST ARVM Rabbit IB: 1:1000 
P-AMPK (Thr172) CST ARVM/mouse heart Rabbit IB: 1:1000 
P-Erk (Thr202/Tyr204) CST ARVM/mouse heart Rabbit IB: 1:1000 
P-mTOR (Ser4228) CST ARVM Rabbit IB: 1:1000 
P-P70S6K 
(Thr421/Ser424) 
CST ARVM Rabbit IB: 1:1000 
P-S6K (Ser235/236) CST ARVM Rabbit IB: 1:1000 
Table 1. Information for antibodies used in this study.  
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The left ventricle was quickly dissected from mouse hearts, rinsed in ice-
cold PBS, and immediately frozen using steel clamps cooled with liquid 
nitrogenFrozen tissue pieces were added to tissue lysis buffer containing 20 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH=7.4), 50 mM β-
Glycerol phosphate, 2 mM ethylene glycol tetraacetic acid (EGTA), 1 mM 
dithiothreitol (DTT), 10 mM sodium fluoride (NaF), 1 mM sodium orthovanadate 
(NaVO4), 1% Triton-X 100, 10% Glycerol supplemented with 1 
ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor tablet (Roche) 
added prior to tissue lysis. The tissue was homogenized on ice using a 
mechanical tissue homogenizer (Fisher) and the cells were left to lyse for 30 
minutes on ice. The lysates were cleared by centrifugation (13,000 rpm, 10 min, 
4 °C) and the supernatant was stored at -80 °C. For western blotting, the same 
protocol described in section 2.4.1 was used to evaluate protein expression. 
2.5 HFHS diet mouse model of MHD 
The HFHS-fed mouse recapitulates clinical features of the metabolic 
syndrome in mice and allows us to study aspects of diet-induced cardiac 
dysfunction (concentric cardiovascular hypertrophy and impaired ventricular 
relaxation) in a pathophysiologically relevant mouse model (43). In our studies 
we have observed a thickening of the left ventricular wall and relaxation 
abnormalities that begin early during the time-course of diet and plateau between 
4 and 8 months of HFHS feeding. Myocardial hypertrophy and diastolic 
dysfunction are both ameliorated when mice fed HFHS are co-administered a 
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synthetic polyphenol antioxidant compound, S17834. These data suggest that 
ROS are involved in the pathogenesis of hypertrophy and ventricular relaxation in 
metabolic syndrome. 
2.6 ALDH2-KO mouse model 
The ALDH2-KO mouse was created by targeting a neomycin gene at exon 
3 in the C57BL/6 mouse genome (132). Drug resistant clones that had 
undergone homologous recombination were confirmed to contain the mutant 
allele by Southern blot analysis. In ALDH2-KO mice the expression of the ALDH2 
protein was assessed in liver mitochondrial fractions and no immunoreactive 
bands were observed. This mouse has no significant cardiac phenotype at 
baseline but is sensitive to ethanol and the toxic byproduct acetaldehyde. 
Cardiac ischemia-reperfusion injury is greater in this mouse, and is associated 
with increased cardiomyocyte dysfunction and HNE adduct formation. This 
mouse model and a number of other aspects of ALDH2 biology were recently 
summarized in a comprehensive review by Chen et al (133). The role of 
metabolic stress in these mice has to date not been evaluated. 
2.7 HNE adduct detection in HEK293T cells 
HEK293T cells expressing GST-LKB1, STRAD, and MO25 were scraped 
in cell lysis buffer (CST) containing 1mM PMSF and allowed to lyse for 30 
minutes on ice. The lysates were centrifuged for 10 min at 13,000 rpm and the 
supernatants were removed for analysis. The GST-LKB1 proteins were immuno-
precipitated using Glutathione-Sepharose 4B beads (GE Healthcare) overnight at 
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4 °C. The purified proteins were washed three times with lysis buffer and 
resuspended in Laemmli sample loading buffer (Bio-Rad) prior to Western 
blotting. Membranes were immuno-blotted with rabbit anti-GST antibody and 
goat anti-HNE antibody, and visualized using the Li-COR Odyssey IR imager. 
Intensity of the bands representing HNE adducts were normalized against the 
bands for GST for each sample. 
2.8 LKB1 activity assay 
2.8.1 Activity assay in HEK293T cells 
Lysates expressing GST-LKB1 were incubated with Glutathione-
Sepharose 4B beads overnight at 4 °C. The purified proteins were washed twice 
with cell lysis buffer and once with 1X kinase assay buffer (CST). The purified 
proteins were incubated with 1X kinase assay buffer containing the LKBtide 
synthetic substrate (300 µM; Millipore), ATP (200 µM), and [γ-32P] ATP (5 µCi). 
After incubation at 30 °C for 20 min, the reaction mixture was spotted on P81 
phosphate paper and washed, and radioactivity was measured by liquid 
scintillation counting. 
2.8.2 Activity assay in ARVM and heart tissue lysates 
Protein G beads (GE Healthcare) were washed three times with PBS and 
conjugated to the LKB1 antibody (Santa Cruz, M-18) for 1 hour at 4 0C. 500 ug 
protein of each sample was added to 40 µL of the antibody-bead complex, 
brought up to an equal volume using Homogenization Buffer (62.5 mM Tris-HCl, 
5 mM EDTA, 5 mM EGTA, pH=7.5) and rotated end on end overnight at 4 0C. 
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The immuno-preciptated proteins were washed twice with Homogenization Buffer 
and twice with Kinase Wash Buffer (40 mM HEPES, 80 mM  sodium chloride 
(NaCl), 0.8 mM EDTA, 5 mM magnesium chloride (MgCl2), 800 µM DTT, 8% 
Glycerol, pH=7.5). To verify that the immuno-precipitation reaction was 
specifically pulling down LKB1, I used heart lysates from mice with LKB1 deleted 
only in the cardiomyocyte and immuno-blotted with a different LKB1 antibody 
(CST, D60C5) (Figure 3). 
To conduct the activity assay, the immuno-precipitated LKB1 was incubated with 
kinase assay buffer containing the LKBtide synthetic substrate (300 µM, 
Millipore), HEPES (40 mM), DTT (800 µM), NaCl (80 mM), EDTA (800 µM), 
Glycerol (8%), ATP (200 µM), and P32-radioactively labeled ATP.  After 
incubation at 37 0C for 20 minutes, the reaction mixture was spotted on P81 
phosphate paper, washed thoroughly, and radioactivity was measured by liquid 
scintillation counting. To verify that the activity assay is specific for LKB1 protein I 
again utilized heart lysates from mice with cardiomyocyte-specific deletion of 
LKB1 (Figure 4). The results show that LKB1 activity is decreased with 
heterozygote LKB1 expression and is further diminished with complete 
cardiomyocyte loss of LKB1. The residual LKB1 activity is likely caused by the 
contribution of non-cardiomyocyte cells (fibroblasts, smooth muscle cells, 
endothelial cells) that are included in a whole heart lysate. 
2.9 AMPK activity assay 
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Figure 3. Immuno-precipitation of LKB1 from mouse heart. LKB1 was 
immuno-precipitated from mouse heart (LKB1 +/+ and LKB1 -/-) and immuno-
blotted for LKB1 expression. 
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Figure 4. LKB1 activity assay in mouse heart. 
LKB1 was immuno-precipitated from mice with cardiomyocyte specific deletion of 
the LKB1 gene (LKB1 +/+, LKB1 +/-, or LKB1 -/-) and assessed for LKB1 activity 
using the synthetic substrate LKBtide in the presence of [γ-32P]-ATP (n=3-6, # = 
p < 0.05 vs LKB1 +/+, $ = p < 0.01 vs LKB1 +/-). 
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Protein G beads were washed three times with PBS and conjugated to the 
AMPKα2 antibody for 1 hour at 4 0C. 500 ug protein of each sample was added 
to 40 µL of the antibody-bead complex, brought up to an equal volume using 
Homogenization Buffer and rotated end on end overnight at 4 0C. The immuno-
precipitated proteins were washed three times with Homogenization Buffer. The 
purified proteins were incubated with kinase assay buffer containing the SAMS 
synthetic peptide (200 µM, Millipore), DTT (960 µM), ATP (200 µM), and P32-
radioactively labeled ATP.  After incubation at 37 0C for 10 minutes, the reaction 
mixture was spotted on P81 phosphate paper, washed thoroughly, and 
radioactivity was measured by liquid scintillation counting. 
2.10 Cyoplasmic and nuclear cell fractionation 
Localization studies were conducted using the NE-PER Nuclear and 
Cytoplasmic Extraction kit from Thermo Scientific (catalogue number 78833) 
according to the specifications of the manufacturer. Purity of the cytosolic and 
nuclear fractions was assessed by protein expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and histone H3, respectively, and fractions 
with a minimum of 85% purity were used for data analysis. 
2.11 [3H]-leucine incorporation assay 
ARVMs were treated as noted in the figure legends and incubated with 
[3H]-leucine (PerkinElmer Life Sciences) at a concentration of 1 µCi/mL of media. 
After 24 hrs the cells were rinsed twice in ice-cold PBS and were then 
precipitated using ice-cold 5% TCA for 1 hr at 4 0C. Next the cells were rinsed 
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twice using ice-cold Milli-Q water, all residual water was aspirated, and then the 
cells were solubilized using 0.4 M NaOH for 1 hr at room temperature. The 
cellular extracts were collected, mixed with liquid scintillation cocktail, and the 
incorporated radioactivity was measured using a liquid scintillation counter.  
2.12 p21Ras Activity Assay in ARVMs 
The Ras Activity Assay kit was purchased from Millipore (Cat #17-218) 
and used according to the manufacturer’s instructions. Briefly, ARVMs were 
treated as indicated in the figure legends and lysed in ice-cold Mg2+ Lysis/Wash 
buffer. Lysates were cleared by centrifugation (13,000 rpm, 10 minutes, 4 0C) 
and to equal amounts of sample lysate the Ras Assay Reagent (Raf-1 p21Ras 
Binding Domain, conjugated to glutathione agarose beads) was added and 
allowed to rotate overnight at 4 0C. Samples were pelleted, repeatedly washed, 
and the resulting p21Ras protein-bead mixture was resuspended in 2X Laemmli 
reducing sample buffer and used for western blotting analysis. The membrane 
was incubated with the anti-p21Ras antibody included in the kit. Active p21Ras 
was determined by quantifying the p21Ras protein that was bound to the Raf-1 
p21Ras Binding Domain, and the total protein lysate was used to quantify the 
total amount of p21Ras in the sample. This ratio (Active/Total p21Ras) was used 
as the measurement of p21Ras activity in this work. 
2.13 Gene expression analysis in ARVMs 
ARVMs were treated as described and total RNA was isolated using the 
mirVana miRNA Isolation Kit (Life Technologies, AM1560) according to the 
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manufacturer’s recommendations for RNA isolation from cultured cells. 250 ng of 
total RNA was reverse transcribed to cDNA using the High Capacity RNA-to-
cDNA Kit (Applied Biosystems, 4387406). Gene expression of Atrial Natriuretic 
Peptide (ANP) (Nppa, Rn00561661_m1), Sarco/Endoplasmic Reticulum Ca2+-
ATPase 2A (SERCA2A) (ATP2a2, Rn00568762_m1), and MHC-α (Myh6, 
RN00691702_m1) were measured and normalized to GAPDH (Gapdh, Rat 
GAPDH 20X) using the quantitative PCR cycler Real Time PCR StepOnePlus 
(Applied Biosystems). 
2.14 Isolation of cardiac mitochondria 
 Cardiac mitochondria were isolated as described by Liesa et al (134). 
Briefly, hearts were minced in ice-cold relaxation buffer (potassium chloride (KCl) 
100mM, EGTA 5mM, HEPES 5mM, pH=7.4) and homogenized mechanically 
with a tissue homogenizer. The lysate was centrifuged (500g at 10 minutes) and 
the supernatant was further separated (9000g at 15 minutes). The mitochondrial 
pellet was resuspended in homogenization buffer and used for the following 
assays. 
2.15 Mitochondrial oxygen consumption measurements 
 Isolated mitochondria were loaded in a 24-well Seahorse plate in 
mitochondrial assay buffer (Sucrose 70mM, mannitol 220 mM, monopotassium 
phosphate (KH2PO4) 5mM, MgCl2 5mM, HEPES 2mM, EGTA 1mM, pH=7.4) with 
substrates. Complex I measurements were made using Pyruvate and Malate (5 
mM each) and Complex II measurements were conducted using Succinate (5 
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mM) and Rotenone (2 µM). Maximal oxygen consumption rates (State 3) were 
evaluated under conditions of excess substrate and ADP (0.25 mM). 
2.16 ROS production and ATP synthesis measurements 
 Hydrogen peroxide production from cardiac mitochondria was measured 
in the presence of Complex I or II substrates using the Amplex Red reagent (Life 
Technologies). ATP synthesis rates were measured using the ATP 
Bioluminescence Kit CLS II (Roche) according to the manufacturer’s 
recommendations. 
2.17 Statement on animal use 
 The protocols for all animals used in this study (rats and mice) were 
approved by the Institutional Animal Care and Use Committee at Boston 
University School of Medicine. 
2.18 Statistical analysis 
Statistics were performed with a two-tailed unpaired Student’s t test or 
analysis of variance where appropriate. All data shown represent the results 
obtained from independent experiments and data are expressed as means±S.E. 
Values of p < 0.05 were considered statistically significant. 
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Chapter 3: HNE Adducts of LKB1 Occur on Lysine-96 and Lysine-97, and 
HNE Inhibits LKB1 Activity Through Adduct Formation on Lysine-97 
 
3.1 Rationale 
LKB1 was identified as the loss of function gene product in patients with 
the familial cancer disorder Peutz-Jeghers syndrome (105), and has since been 
characterized as a serine/threonine kinase that phosphorylates and activates 
AMPK and twelve other AMPK-related kinases (99). AMPK regulates 
mitochondrial biogenesis (135) and autophagy (136) in addition to other cellular 
processes that promote a net positive energetic balance. Under basal conditions 
LKB1 is localized to the nucleus where it has limited catalytic activity. 
Translocation to the cytosol allows for interaction with the pseudo-kinase 
STRAD, thereby enhancing the cytosolic localization of LKB1 by acting as an 
adaptor between exportins (CRM1 and exportin7) and LKB1 (112). The 
interaction between LKB1, STRAD, and the scaffolding protein MO25 stabilizes 
the heterotrimer, forming a constitutively active complex (110).  Deacetylation of 
LKB1 at Lys-48 by the NAD+-dependent class III deacetylase SIRT1 promotes 
translocation of LKB1 to the cytosol (111), and SIRT3 deacetylates and activates 
LKB1 in the heart (137). 
During states of increased oxidative stress, free radical oxygen species 
interact with polyunsaturated fatty acids to generate lipid peroxyl radicals (54). 
Decomposition of lipid peroxyl radical species by β-cleavage leads to the 
 35 
generation of α,β-unsaturated aldehydes such as MDA and HNE (56). 
Accumulation of HNE has been observed in several tissues (50,51,53,138) and, 
due to its high reactivity, forms covalent protein adducts on cysteine, histidine, 
and lysine residues through the Michael reaction and Schiff base formation on 
lysine and arginine residues (139). Adduction by HNE occurs on proteins 
involved in cellular signaling (60-62,64) including LKB1. HNE adducts of LKB1 
impair downstream AMPK signaling in MCF-7 cells (127) and in cardiac 
myocytes HNE adducts of LKB1 promote downstream hypertrophic signaling 
(140). Our lab recently observed HNE-LKB1 adducts in hearts from mice fed a 
HFHS diet (43). 
The role of lysine acetylation and deacetylation has been studied 
extensively in regards to histone regulation and transcriptional effects, but 
emerging data suggest that non-histone lysine modifications also play a vital role 
in cellular energetic homeostasis. Lysine acetylation of non-histone proteins can 
regulate cellular metabolism (141) and it has been suggested that reversible 
acetylation may be an evolutionarily conserved mechanism by which organisms 
respond to changes in nutrient availability (142). In the cardiovascular system 
deacetylation of lysine residues on key metabolic proteins can modulate 
mitochondrial function through changes in apoptotic signaling, respiratory 
capacity, and ATP synthesis (143). In a previous study from Dr. Yasuo Ido and 
Dr. Neil Ruderman, LKB1 acetylation was found to occur at several lysine 
residues that function to regulate LKB1 localization (111). I now test the 
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hypothesis that inhibitory HNE adducts of LKB1 occur at lysine residues capable 
of being acetylated, thereby regulating enzyme activity. I show that HNE adducts 
to LKB1 at Lys-96 and Lys-97, and that adduction to Lys-97, but not Lys-96, 
inhibits LKB1 kinase activity. 
 
3.2 Experiments 
3.2.1 HNE forms inhibitory adducts of LKB1 and inhibits kinase 
activity 
It was previously reported that HNE concentrations of 40 µM form 
inhibitory adducts on LKB1 in neonatal cardiomyocytes (140). I expressed LKB1 
and its binding partners STRAD and MO25 in HEK293T cells and exposed the 
cells to HNE in concentrations of 1, 2.5, 5, 10, 20, 30, and 40 µM for 1 hr. In cells 
expressing the LKB1 complex, HNE adducts were readily detectable in immuno-
precipitated LKB1 with HNE concentrations of 10 µM and higher (Figure 5), and 
accordingly an HNE concentration of 10 µM was used in the remainder of this 
study. To further confirm the presence of HNE-LKB1 adducts, HNE-bound 
proteins were immuno-precipitated and LKB1 was detected among the HNE-
modified proteins (Figure 6). Coincident with the formation of HNE-LKB1 
adducts, exposure to HNE (10 uM, 1 hr) caused a 31 ± 9% (SEM) decrease in 
LKB1 activity as assessed with a kinase assay using the LKBtide synthetic 
substrate (Figure 7). 
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Figure 5. Dose-dependent formation of HNE-LKB1 adducts. 
HEK293T cells were transiently transfected with GST-LKB1, His-STRAD, and 
FLAG-MO25 and GST-LKB1 was immuno-precipitated and immuno-blotted with 
an anti-HNE antibody at the following doses of HNE: 1, 2.5, 5, 10, 20, 30, 40 µM 
(n=3).  
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Figure 6. Immuno-precipitation of HNE-modified proteins identifies LKB1 as 
an HNE target. 
HEK293T cells were transiently transfected with GST-LKB1, His-STRAD, and 
FLAG-MO25 and cells treated with 10 µM HNE were immuno-precipitated for 
HNE-bound proteins and immuno-blotted for GST-LKB1 association (n=3).  
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Figure 7. HNE inhibits LKB1 activity. 
HEK293T cells were transiently transfected with GST-LKB1, His-STRAD, and 
FLAG-MO25 and LKB1 activity was assessed using the LKBtide synthetic 
substrate in the presence of [γ-32P]-ATP (n=9, ** = p<0.01).  
 
 40 
3.2.2 HNE adduction does not interfere with LKB1-STRAD-MO25 
complex formation 
Since LKB1 kinase activity is greatly enhanced when LKB1 interacts with 
STRAD and MO25, I tested whether HNE interferes with LKB1 complex 
formation and thereby diminishes its activity. Immuno-precipitation of LKB1 and 
subsequent immuno-blotting for STRAD and MO25 demonstrated no effect of 
HNE on LKB1-STRAD-MO25 complex formation (Figure 8). The cellular 
localization of LKB1 is also known to affect its catalytic activity (110). To 
determine if HNE could affect LKB1 localization, protein lysates from cells 
expressing the LKB1 complex were separated into cytoplasmic and nuclear 
fractions. HNE treatment had no effect on the localization of LKB1, STRAD, or 
MO25 (Figure 9), and LKB1 was observed to localize primarily in the cytoplasm 
both with and without HNE (Figure 10). Together these data suggest that the 
inhibitory effect of HNE is due to a direct effect on LKB1 enzymatic function and 
is not related to changes in complex formation or localization. 
 
3.2.3 HNE adducts of LKB1 occur at Lys-96 and Lys-97 
Work by our colleagues Lan et al., demonstrated that several lysine 
residues of LKB1 can be acetylated both in vitro and in vivo (111). Since lysine 
residues may possess important regulatory functions I investigated whether they 
are targeted for HNE adduction. I used three LKB1 mutants in which lysine 
residues were mutated to arginine, a mutation that mimics the effects of  
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Figure 8. HNE has no effect on LKB1-STRAD-MO25 complex formation. 
HEK293T cells were transiently transfected with GST-LKB1, His-STRAD, and 
FLAG-MO25 and immuno-precipitated GST-LKB1 was immuno-blotted for 
protein-protein interactions of LKB1 with associated proteins STRAD and MO25 
(n=3).  
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Figure 9. HNE has no effect on LKB1, STRAD, or MO25 localization. 
HEK293T cells were transiently transfected with GST-LKB1, His-STRAD, and 
FLAG-MO25 and the cytosolic and nuclear fractions of cells expressing the LKB1 
complex were isolated and immuno-blotted for LKB1 complex proteins (n=3).  
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Figure 10. Quantification of LKB1 expression in cytosolic and nuclear 
compartments. 
HEK293T cells were transiently transfected with GST-LKB1, His-STRAD, and 
FLAG-MO25 and the cytosolic and nuclear fractions of cells expressing the LKB1 
complex were quantified for LKB1 protein in the cytosolic and nuclear cellular 
fractions (n=3, * = p < 0.05).  
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deacetylation (144) and decreases the chemical affinity of HNE for the mutated 
residue. The mutants were expressed in HEK293T cells and screened for the 
ability of HNE to form covalent adducts. Mutation of lysines 96 (K96R) and 97 
(K97R) each decreased HNE adduct formation (Figures 11 and 12). Interestingly, 
mutation of Lys-96 and Lys-97 together (K96-97R) caused a greater decrease in 
HNE adduct formation than either Lys-96 or Lys-97 alone (Figure 13). Immuno-
precipitation of HNE-bound proteins confirmed that there was a decreased 
amount of HNE-LKB1 adducts in the K96-97R mutant (Figure 14). 
 
3.2.4 HNE adduct formation at Lys-97 inhibits LKB1 kinase activity 
The finding that HNE adduct formation is decreased by mutation of LKB1 
lysines 96 or 97 raised the possibility that these mutants would be resistant to the 
inhibitory effect of HNE. However, the kinase activity of the K96R mutant was 
inhibited by HNE to the same extent as wildtype LKB1 (Figure 15). In contrast, 
kinase activity of the K97R mutant was resistant to inhibition (Figure 16), as was 
the K96-97R LKB1 mutant (Figure 17). Interestingly, the K97R and K96-97R 
mutants, but not the K96R mutant, exhibited an approximately 2-fold increase in 
basal kinase activity as compared to wildtype LKB1. 
 
3.2.5 Modification of LKB1 by HNE occurs at amino acid residues 
other than Lys-96 and Lys-97 
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Figure 11. Mutation of LKB1 Lys-96 decreases HNE-adduct formation. 
HEK293T cells were transiently transfected with plasmids encoding wildtype or 
K96R GST-tagged LKB1, STRAD, and MO25. The cells were treated with HNE 
and assayed for HNE-adduct formation with the quantification of HNE-LKB1 
adducts (n=3-5, * = p < 0.05).  
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Figure 12. Mutation of LKB1 Lys-97 decreases HNE-adduct formation. 
HEK293T cells were transiently transfected with plasmids encoding wildtype or 
K97R GST-tagged LKB1, STRAD, and MO25. The cells were treated with HNE 
and assayed for HNE-adduct formation with the quantification of HNE-LKB1 
adducts (n=3-5, * = p < 0.05).  
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Figure 13. Mutation of LKB1 Lys-96 and Lys-97 dramatically decreases 
HNE-adduct formation. 
HEK293T cells were transiently transfected with plasmids encoding wildtype or 
K96R/K97R GST-tagged LKB1, STRAD, and MO25. The cells were treated with 
HNE and assayed for HNE-adduct formation with the quantification of HNE-LKB1 
adducts (n=3-5, ** = p < 0.01).  
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Figure 14. Mutation of LKB1 Lys-96 and Lys-97 decreases immuno-
precipitation of HNE-modified LKB1. 
HEK293T cells were transiently transfected with plasmids encoding wildtype or 
K96R/K97R GST-tagged LKB1, STRAD, and MO25. HNE-modified proteins were 
immuno-precipitated with an anti-HNE antibody and immuno-blotted for GST-
LKB1 association. (n=3 ** = p <0.01).  
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Figure 15. Mutation of LKB1 Lys-96 has no effect on inhibition of LKB1 by 
HNE. 
HEK293T cells expressing WT or K96R LKB1, STRAD, and MO25 were treated 
with HNE (10 µM, 1 hr) and immuno-precipitated LKB1 was assayed for kinase 
activity (n=5, * = p <0.05, 1-way ANOVA, Bonferroni’s post-test). Expression of 
GST-tagged LKB1 constructs was confirmed in cellular lysates. 
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Figure 16. Mutation of LKB1 Lys-97 prevents HNE-mediated LKB1 
inhibition.  
HEK293T cells expressing WT or K97R LKB1, STRAD, and MO25 were treated 
with HNE (10 µM, 1 hr) and immuno-precipitated LKB1 was assayed for kinase 
activity (n=5, * = p <0.05, ** = p<0.01, 1-way ANOVA, Bonferroni’s post-test). 
Expression of GST-tagged LKB1 constructs was confirmed in cellular lysates. 
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Figure 17. Mutation of LKB1 Lys-96 and Lys-97 prevents HNE-mediated 
LKB1 inhibition.  
HEK293T cells expressing WT or K96R/K97R LKB1, STRAD, and MO25 were 
treated with HNE (10 µM, 1 hr) and immuno-precipitated LKB1 was assayed for 
kinase activity (n=5, * = p <0.05, ** = p<0.01, 1-way ANOVA, Bonferroni’s post-
test). Expression of GST-tagged LKB1 constructs was confirmed in cellular 
lysates. 
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In Figures 11 and 12, the mutation of LKB1 lysine residues decreases HNE 
adduct formation but does not eliminate the detection of HNE adducts on the 
LKB1 protein. This suggests that other amino acids of LKB1 and/or the GST tag 
are targets of HNE adduct formation. To address if HNE can form adducts on the 
GST tag I expressed another GST-tagged protein, beta-glucuronidase (GUS), in 
HEK293T cells and treated with HNE. I observed that without any HNE treatment 
the GUS protein itself was immunoreactive with the HNE antibody. However, 
treatment with HNE didn’t further increase HNE adduct detection, leading us to 
conclude that the GST tag as well as the GUS protein are not targets of HNE 
(Figure  18). To address if other amino acids of LKB1 could be targeted by HNE, 
I expressed LKB1 constructs that lack the first 190 amino acids on the N-
terminus of the protein. Treatment of HEK293T cells expressing these truncated 
constructs with HNE produced a detectable HNE-LKB1 adduct (Figure 19). 
These data support the notion that amino acid residues aside from Lys-96 and 
Lys-97 of LKB1 are targets of HNE adduct formation.  
 
3.3 Discussion 
The goal of this study was to determine the mechanism by which HNE 
inhibits LKB1 kinase activity. Our major findings are that a) HNE inhibition of 
LKB1 kinase activity does not involve disruption of LKB1 translocation or 
complex formation, b) HNE forms adducts with LKB1 at Lys-96 and Lys-97, and  
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Figure 18. The GST tag of the GST-LKB1 construct is not a target for HNE-
adduct formation. 
HEK293T cells expressing GST-LKB1 or GST-GUS were treated with HNE (10 
µM, 1 hr) and immuno-precipitated for GST-containing proteins. The GST-tagged 
proteins were then immuno-blotted with an anti-HNE antibody to detect any HNE 
associated proteins (n=3). 
 
 54 
 
 
 
 
Figure 19. LKB1 residues besides Lys-96 and Lys-97 are targeted for HNE-
adduct formation. 
HEK293T cells expressing full length LKB1 (1-436) or truncated LKB1 (190-310 
or 190-436) were treated with HNE (10 µM, 1 hr) and immuno-precipitated. The 
proteins were then immuno-blotted with an anti-HNE antibody to detect any HNE 
associated proteins (n=3). 
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c) targeted mutation of Lys-97, but not Lys-96, prevents the inhibitory action of 
HNE. 
The ability of HNE to form adducts with LKB1 was demonstrated by 
immuno-precipitating LKB1 and immuno-blotting for HNE adducts, and was 
confirmed by pulling down HNE-modified proteins and probing for associated 
LKB1. The formation of HNE-LKB1 adducts was first observed in MCF-7 cells 
(127). It was noted that Cys-210 is an evolutionarily conserved cysteine residue 
among a number of serine/threonine kinases and is a target for lipid adduction. 
While Cys-210 appears capable of mediating lipid adduct formation, as 
demonstrated by loss of the ability of reactive lipids to form adducts against LKB1 
in which Cys-210 is mutated to serine, the effects of HNE adduction on LKB1 
activity and/or downstream signaling were not determined. More recently, it was 
shown that HNE can adduct to LKB1 and is associated with inhibition of enzyme 
activity and increased hypertrophic signaling stemming from changes in the 
LKB1-AMPK signaling axis (140). 
I next confirmed that HNE inhibits LKB1 enzymatic activity. I measured 
LKB1 kinase activity directly using the synthetic substrate LKBtide, a well-
validated approach (111,140,145,146) have used. Phosphorylation at Ser-428 
may also be used to measure LKB1 activity, as it is correlated with increased 
activity and is thought to be required for LKB1-dependent functions in some cell 
types (125). However, phosphorylation at Ser-428 isn’t necessary for all kinase-
dependent functions of the protein (124). Furthermore, a novel alternative LKB1 
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splice variant has been identified which lacks a portion of the C-terminal domain 
containing Ser-428, yet possesses catalytic activity on a par with the full length 
LKB1 gene product (123). 
To determine the mechanism by which HNE inhibits LKB1 activity, I first 
examined whether HNE interfered with LKB1 translocation or complex formation. 
HNE had no effect on the translocation of LKB1 as assessed by the distribution 
of protein between the nucleus and cytosol. Likewise, HNE inhibited LKB1 
activity without disruption of complex formation as measured by the association 
of LKB1 with its binding partners STRAD and MO25. 
I next used site-directed mutants of LKB1, in which lysine is mutated to 
arginine, to test the role of specific lysine residues in mediating the effects of 
HNE. Since arginine cannot be acetylated, this mutation mimics the effect of 
deacetylation, and also decreases the chemical affinity of the residue for HNE. 
Mutations of Lys-96 or Lys-97 decreased the formation of HNE adducts to a 
similar degree, and mutation of Lys-96 and Lys-97 together caused a roughly 
additive decrease in HNE adduction, indicating that both Lys-96 and Lys-97 are 
sites of HNE adduction. 
In contrast to the similar effects the K96R and K97R mutants have on 
HNE adduct formation, only the K97R mutant was protected from inhibition by 
HNE. Enzyme activity was also protected in the K96R/K97R mutant.  Thus, while 
HNE can adduct to both Lys-96 and Lys-97, adduct formation at Lys-97 alone is 
sufficient to mediate enzyme inhibition. These findings suggest that HNE inhibits 
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LKB1 activity via a direct post-translational modification at Lys-97. Aside from 
modification by HNE, no other direct oxidative post-translational modifications of 
LKB1 have been described. The reactive nitrogen species peroxynitrite (ONOO-) 
has been shown to regulate LKB1 activity indirectly through activity of upstream 
protein kinase C zeta in the endothelium (147).  
Based on these findings I cannot exclude other sites at which HNE 
adduction occurs on the LKB1 protein. It is conceivable that amino acid residues 
aside from Lys-96 and Lys-97 are targets of HNE. Further studies in our lab 
suggest that the GST tag of the protein isn’t a target but amino acids in other 
domains of the protein may be targeted by HNE. 
It is noteworthy that basal enzyme activity was increased approximately 2-
fold in both the K97R and K96R/K97R mutants. Lys-97 is a known target of 
acetylation (111). Modification of this residue by acetylation, methylation, 
SUMOylation, or ubiquitination could potentially modulate kinase function of 
LKB1. More studies will need to be carried out to delineate the precise 
mechanism by which mutation of Lys-97 increases LKB1 kinase activity. 
The structure of HNE contains three functional groups (C=C double bond, 
C=O carbonyl group, and the hydroxyl group) which are responsible for the high 
reactivity of this electrophilic aldehyde (139). While carbon 3 is the primary site of 
nucleophilic attack by thiol or amine groups via the Michael reaction, the carbonyl 
carbon 1 is a secondary target of primary amines through Schiff base formation. 
Using synthetic poly-amino acid model compounds, HNE was shown to 
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chemically react in the following order: Cys>His>Lys (148). It was noted that this 
order doesn’t implicate cysteine residues as the preferred targets of HNE. 
Depending on the overall quaternary protein structure as well as the surrounding 
amino acid residues, the reactivity of HNE towards amine containing amino acids 
can be enhanced. 
A noteworthy aspect of this study is the use of a low concentration of HNE 
(10 µM). The concentration of HNE in human plasma ranges from 0.3 to 0.7 µM 
(57) but can reach levels as high as 10 µM under conditions of oxidative stress 
(58). Studies investigating HNE-mediated changes in LKB1 signaling used an 
HNE concentration of 40 µM (140), which resulted in significant degradation of 
the LKB1 protein within one hour. Pathophysiological responses to HNE 
treatment in cardiac myocytes with concentrations as high as 400 µM have been 
reported to include calcium overload and reactive oxygen species generation 
(87). HNE has been shown to stimulate autophagy (149), ubiquitin-mediated 
proteasomal degradation of proteins (150,151) and to elicit an ER-stress 
response in cultured vascular smooth muscle cells (152). By using a relatively 
low concentration of HNE, our findings are less likely to be confounded by 
cellular events that may be activated with higher concentrations. 
 In summary, this study provides compelling evidence that post-
translational modification of LKB1 via HNE adduct formation at Lys-97 is 
responsible for the inhibitory effect of this lipid peroxidation byproduct on kinase 
activity. Inhibition of LKB1 during states of increased oxidative stress and 
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secondary lipid peroxidation could lead to energetic impairment and cellular 
dysfunction. 
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Chapter 4: HNE-Induced Hypertrophy in Cultured ARVMs Occurs Via both 
decreased LKB1-AMPK signaling and activated Erk signaling. 
 
4.1 Rationale 
HF is the progressive deterioration of the heart’s ability to circulate blood 
to peripheral tissues, leading to compensatory cardiac remodeling in order to 
maintain adequate cardiac output (3). One important aspect of cardiac 
remodeling is left ventricular hypertrophy (LVH), in which individual 
cardiomyocyte growth is regulated by numerous signaling pathways (153). LVH 
has been associated with increased ROS production, and it is well accepted that 
ROS have important roles in regulating myocardial growth via oxidative post-
translational modification (OPTM) of key signaling proteins (154). For example 
our lab has demonstrated that OPTM of p21Ras on reactive Cys residues 
activates downstream Erk1/2 signaling to promote hypertrophy in cardiomyocytes 
(33). While it is understood that ROS can directly alter cellular signaling, the 
secondary effects of ROS that occur due to lipid peroxidation-derived reactive 
aldehydes are only beginning to be investigated (55).  
Lipid peroxidation byproducts are formed when free radical oxygen 
species abstract hydrogen from polyunsaturated fatty acids to form lipid peroxyl 
radicals (54). This radical species undergoes a β-cleavage reaction which 
generates reactive aldehyde species such as HNE (56). HNE modifies proteins 
through the formation of covalent protein adducts via the Michael addition 
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reaction (Cys, His, Lys, Arg) or through Schiff base formation (Lys, Arg) (139). 
HNE and other reactive aldehydes are increased in the plasma of HF patients 
(68) and patients with dilated cardiomyopathy exhibit myocardial HNE-protein 
modifications that were decreased after treatment with carvedilol, a vasodilating 
β-blocker with antioxidant activity (69). In a mouse model of systolic HF caused 
by cardiomyocyte-specific Gαq transgene expression, Gαq hearts have 
increased HNE levels and cardiac hypertrophy which were both ameliorated by 
transgenic expression of the antioxidant catalase (34). In a diet-induced mouse 
model of HF with preserved ejection fraction, our lab has observed increased 
HNE-protein modifications and myocardial hypertrophy that were both decreased 
when polyphenols were co-administered with the diet (43). 
Based on these associations between cardiac hypertrophy and increased 
HNE content, I hypothesized that HNE could directly promote cellular growth via 
protein modifications that increase hypertrophic signaling. The LKB1-AMPK 
signaling cascade is an important hypertrophic regulatory pathway that is 
impaired by HNE (127). Inhibition of LKB1 function was found to decrease AMPK 
activity and promote hypertrophic signaling through increased phosphorylation of 
the downstream proteins mTOR and P70S6K. Furthermore in the spontaneously 
hypertensive rat myocardial hypertrophy was associated with increased HNE-
LKB1 adduct formation and hypertrophic activation of mTOR and p70S6K. 
Administration of the antioxidant resveratrol decreases both cardiac hypertrophy 
and HNE levels, as well as to prevent the inhibition of the LKB1-AMPK signaling 
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pathway (63). While this study has been of significant value in demonstrating the 
efficacy of resveratrol in decreasing myocardial HNE levels and restoring activity 
of the LKB1-AMPK kinases, it remains to be determined if the HNE-mediated 
signaling changes directly cause cardiac hypertrophy. Furthermore, the ability of 
HNE to stimulate other hypertrophic signaling pathways has not been addressed. 
As an extension of that work I now test the hypothesis that HNE could directly 
promote cardiomyocyte hypertrophy, and that this occurs via inhibition of LKB1-
AMPK signaling and activation of other hypertrophic signaling cascades, namely 
the MAPK pathway.  
 
4.2 Experiments 
4.2.1 HNE induces protein synthesis in cultured cardiomyocytes 
My prior work has shown that 10 µM HNE inhibits LKB1 activity through 
the formation of HNE-adducts in HEK293T cells (155) and others have shown 
that HNE treatment impairs LKB1-AMPK signaling in cardiomyocytes (63). Based 
on these observations of hypertrophic signaling changes, I sought to determine if 
HNE treatment would directly promote increased protein synthesis. Cultured 
ARVMs were treated with 10 µM HNE for 1 hour, after which the media was 
removed and replaced with HNE-free media containing [3H]-leucine. After 24 
hours the cells were collected and HNE treatment was observed to increase [3H]-
leucine incorporation by 24.2 ±2.4% (S.E.) (Figure 20) suggesting that HNE can 
directly stimulate cellular growth. 
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Figure 20. HNE increases protein synthesis in ARVMs. 
ARVMs were treated with 10 µM HNE for 1 hour, after which the media was 
removed and replaced with fresh media containing [3H]-leucine. After 24 hours 
the cells were collected and assayed for incorporation of the labeled leucine by 
liquid scintillation counting (n=5, * = p < 0.05, error bars are mean ± standard 
error).  
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4.2.2 Fetal genes are not activated by HNE  
In failing hearts and cultured cardiomyocytes exposed to hypertrophic 
stimuli a “fetal gene program” is activated, presumably as a way for the cell to 
express the proteins necessary to recapitulate the growth phase of the 
developing heart (156). To test if HNE-induced hypertrophy involves changes in 
fetal gene expression, ARVMs were treated with 10 µM HNE for 1 hour, after 
which the media was removed and replaced with HNE-free media and the cells 
were left to incubate for 24 hrs. As a positive control, another set of cells was 
treated with Norepinephrine (NE) for 24 hrs. Total RNA was isolated and 
evaluated for changes in gene expression of ANP, SERCA2A, and α-MHC. 
Whereas NE strongly induced ANP and suppressed SERCA2A, HNE had no 
effect on ANP and only a slight inhibitory effect on the decrease in SERCA2A 
gene expression (Figure 21). Expression of α-MHC was slightly decreased with 
NE treatment, and HNE had no effect on α-MHC gene expression. These data 
indicate that HNE increases protein synthesis in myocytes without induction of 
hypertrophic gene expression changes. 
 
4.2.3 HNE causes hypertrophic signaling changes along the LKB1-
AMPK signaling axis 
Having observed that HNE directly promotes increased protein synthesis, I 
next investigated potential signaling mechanisms that could mediate this effect. 
The earlier observations that HNE inhibits LKB1-AMPK signaling utilized  
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Figure 21. Fetal genes are not activated by HNE treatment. 
ARVMs were treated with 10 µM HNE for 1 hour, after which the media was 
removed and replaced. After 24 hours total RNA was isolated from cells and 
evaluated for gene expression changes for the indicated genes (n=3, * = p < 
0.05, error bars are mean ± standard error).  
 66 
neonatal cardiomyocytes, and due to differential responses of adult and neonatal 
ventricular cardiomyocytes to hypertrophic stimuli (157), I sought to first 
investigate if the same hypertrophic pathways were altered by HNE treatment in 
ARVMs. HNE treatment (10 µM, 1 hour) induced detectable HNE-adducts as 
observed by immuno-precipitation of LKB1 and immuno-blotting for the HNE 
modification (Figure 22). In cells treated with HNE there was a 24.8 ±12.2% 
(S.E.) decrease in LKB1 activity (Figure 23), which is consistent with the 
inhibitory HNE modification. To determine if HNE treatment impacted 
downstream LKB1 signaling I investigated AMPK, a major substrate for LKB1 in 
the heart. HNE treatment decreased activity of the AMPK alpha2 isoform by 49.7 
±5.4% (S.E.) (Figure 24). Acetyl-CoA Carboxylase (ACC), a downstream 
substrate of AMPK that regulates fatty acid oxidation, was dephosphorylated by 
HNE treatment (Figure 25), which is consistent with the inhibition of AMPK. 
AMPK promotes energetic homeostasis by altering a variety of metabolic 
processes, including the regulation of cell growth through the mTOR/P70S6K 
signaling axis. I investigated the activation status of these signaling proteins and 
observed that HNE increased the phosphorylation of mTOR, P70S6K, and S6K 
(Figure 26-28), which is consistent with the hypothesis that HNE promotes 
cellular signaling through inhibition of the LKB1-AMPK signaling axis.  
 
4.2.4 HNE stimulates Erk1/2 in an ROS and p21Ras independent 
manner 
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Figure 22. The formation of HNE-LKB1 adducts occurs in ARVMs. 
LKB1 was immuno-precipitated from homogenates of cultured ARVMs incubated 
for 1 hour with 10 µM HNE. Immuno-precipitated LKB1 was analyzed by 
immuno-blotting for HNE adduct formation by densitometry and normalized to 
total LKB1 as a control for loading (n=6-7, * = p <0.05).  
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Figure 23. HNE inhibits LKB1 kinase activity in ARVMs. 
LKB1 activity was assessed using the LKBtide synthetic substrate in the 
presence of [γ-32P]-ATP in homogenates of cultured ARVMs incubated for 1 hour 
with 10 µM HNE (n=6-7, * = p <0.05).  
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Figure 24. HNE inhibits AMPK kinase activity in ARVMs. 
AMPK activity was assessed using the SAMS synthetic substrate in the presence 
of [γ-32P]-ATP in homogenates of cultured ARVMs incubated for 1 hour with 10 
µM HNE (n=6-7, * = p <0.05).  
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Figure 25. HNE decreases phosphorylation of ACC. 
ARVMs were incubated for 1 hour with 10 µM HNE and the levels of 
phosphorylated ACC (P-ACC) were quantified by densitometry and normalized to 
total ACC (T-ACC) and GAPDH (n=3, * = p <0.05).  
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Figure 26. HNE increases phosphorylation of mTOR. 
ARVMs were incubated for 1 hour with 10 µM HNE and the levels of 
phosphorylated mTOR (P-mTOR) were quantified by densitometry and 
normalized to total mTOR (T-mTOR) and GAPDH (n=3, * = p <0.05).  
 72 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. HNE increases phosphorylation of p70S6K. 
ARVMs were incubated for 1 hour with 10 µM HNE and the levels of 
phosphorylated p70S6K (P-p70S6K) were quantified by densitometry and 
normalized to total p70S6K (T-p70S6K) and GAPDH (n=3, * = p <0.05).  
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Figure 28. HNE increases phosphorylation of S6K. 
ARVMs were incubated for 1 hour with 10 µM HNE and the levels of 
phosphorylated S6K (S6K) were quantified by densitometry and normalized to 
GAPDH (n=4, * = p <0.05).  
 74 
I have demonstrated that HNE promotes hypertrophic signaling and that 
these signaling changes are associated with cardiomyocyte growth. The 
inhibition of LKB1-AMPK signaling by itself could explain the increase in protein 
synthesis, but since HNE is a non-specific aldehyde the hypertrophic effect could 
result from the activation of other hypertrophic signaling cascades, perhaps in 
addition to the inhibition of LKB1-AMPK signaling. The PI3K/Akt signaling axis 
regulates cellular signaling in response to nutrient availability in part through the 
interaction with 4E-BP1 and S6K (158). Due to the possibility that Akt could alter 
hypertrophic S6K signaling independently of AMPK, I sought to determine if HNE 
had an effect on Akt activation. I found that Akt phosphorylation at Ser-473 was 
unaffected by HNE treatment (Figure 29) which suggests Akt is not active and 
that the hypertrophic signaling is due to inhibition of the LKB1-AMPK cascade. 
MAPK signaling is a potent pro-hypertrophic signaling cascade in 
cardiomyocytes stimulated by α-adrenergic receptor agonists (131). If HNE 
stimulates MAPK signaling, that is another potential mechanism for the increased 
protein synthesis observed with HNE treatment. ARVMs treated with HNE have 
increased phosphorylation of Erk1/2, suggesting that HNE stimulates the MAPK 
pathway (Figure 30). Using the MEK1/2 inhibitor U0126 I observed that the effect 
of HNE was dependent on the upstream Erk1/2 kinase MEK1/2 (Figure 31).  
Earlier studies from our lab have demonstrated that ROS are able to 
stimulate Erk1/2 activation, an effect that has been associated with hypertrophy 
of cultured cardiomyocytes (159). Since HNE can produce ROS (66), I  
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Figure 29. HNE has no effect on Akt activation. 
Homogenates of ARVMs incubated for 1 hour with 10 µM HNE were evaluated 
for levels of phosphorylated Akt (P-Akt) by immuno-blotting. Protein loading was 
normalized to total Akt (T-Akt) and GAPDH (n=3).  
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Figure 30. HNE increases Erk1/2 phosphorylation. 
ARVMs were incubated for 1 hour with 10 µM HNE and the levels of 
phosphorylated Erk1/2 (P-Erk) were quantified by densitometry and normalized 
to total Erk1/2 (T-Erk) and GAPDH (n=4, ** = p <0.01).  
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Figure 31. Activation of Erk1/2 by HNE is dependent on MEK activity. 
ARVMs were incubated with vehicle or U0126 (10 µM) for 30 minutes prior to 
stimulation by HNE. Lysates were immuno-blotted for levels of P-Erk and 
normalized to T-Erk and GAPDH (n=4, * = p <0.05).  
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hypothesized that Erk1/2 activation in ARVMs treated with HNE may be caused 
directly by ROS, as opposed to the formation of an HNE-protein adduct 
promoting Erk1/2 phosphorylation. To test this hypothesis I utilized the 
catalase/SOD mimetic Mn(III)terakis(1-methyl-4-pyridyl) porphyrin pentachloride 
(MnTMPyP) to quench HNE-mediated ROS formation. Pretreatment with 
MnTMPyP did not alter the Erk1/2 response to HNE, yet prevented NE-induced 
Erk1/2 activation, demonstrating the antioxidant compound is effective in ARVMs 
and that ROS are not involved in HNE-mediated Erk1/2 activation (Figure 32). 
Having ruled out the role of an ROS-dependent effect of HNE on Erk1/2 
activation, I next sought to determine if the activation of Erk1/2 occurs through 
the canonical MAPK signaling cascade. Other studies from our lab have shown 
that α-AR stimulation results in an oxidative modification on p21Ras, thus 
activating the protein and promoting hypertrophy downstream through the MAPK 
cascade (33). Therefore I hypothesized that HNE could directly modify p21Ras 
and lead to the activation of Erk1/2 through the canonical MAPK signaling 
cascade. To test this hypothesis ARVMs were treated with HNE or NE (as a 
positive control) and assessed for p21Ras activation using the Ras Activation 
Assay Kit. Whereas NE is a potent activator of p21Ras, HNE failed to increase 
p21Ras activity yet still stimulates downstream Erk1/2 (Figure 33).  
 
4.2.5 Erk1/2 contributes to the activation of S6K with HNE treatment 
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Figure 32. HNE-mediated Erk1/2 activation is not ROS dependent. 
ARVMs were incubated with MnTMPyP (10 µM) for 30 minutes prior to 
stimulation by HNE (10 µM, 60 minutes) or NE (1 µM, 20 mins). Lysates were 
immuno-blotted for levels of P-Erk,T-Erk, and GAPDH (n=4).  
 
 
 
 
 
 
 
 80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. HNE does not alter p21Ras activity. 
ARVMs were incubated with HNE (10 µM, 60 minutes) or NE (1 µM, 20 mins) 
and the cellular lysates were incubated with a p21Ras substrate and immuno-
blotted for association between active p21Ras and the substrate. Lysates were 
then immuno-blotted for p21Ras and phosphorylation of Erk1/2 (n=3, ** = p 
<0.01).  
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In cardiomyocytes hypertrophic stimuli have been shown to activate S6K, 
an effect that is dependent on both MEK-Erk1/2 and mTOR signaling (30). Based 
on this information, I sought to determine if HNE-stimulated Erk1/2 activation was 
responsible for potentiating S6K signaling and to investigate potential interactions 
between the MEK-Erk1/2 and LKB1-AMPK cascades with HNE treatment. In the 
presence of U0126, HNE-stimulated S6K activation was decreased compared to 
the robust S6K activation observed with vehicle pretreatment (Figure 34). This 
differential HNE-stimulated S6K phosphorylation suggests that Erk1/2 signaling 
contributes to the activation of S6K. In order to determine if decreased S6K 
phosphorylation alters protein synthesis, I examined HNE-stimulated protein 
synthesis in the presence of U0126. With U0126 treatment I observed HNE-
stimulated protein synthesis, which was decreased compared to the vehicle-
treated group but was not statistically significant (Figure 35). Studies in 
melanoma cells have shown that LKB1 can be phosphorylated by Erk1/2 and 
p90RSK, thus interfering with the LKB1-AMPK interaction to allow for 
unrestricted cellular proliferation (160). To address if Erk1/2 is inhibiting LKB1-
AMPK signaling, I examined activation of the AMPK substrate ACC in the 
presence of U0126 and observed that U0126 had no effect on HNE-stimulated 
dephosphorylation of ACC (Figure 36). This suggests that the effects of Erk1/2 
on S6K occurs independent of inhibited LKB1-AMPK signaling. 
 
4.2.6 mTOR is required for the activation of S6K by HNE 
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Figure 34. HNE contributes to S6K phosphorylation. 
ARVMs were incubated with vehicle or U0126 (10 µM) for 30 minutes prior to 
stimulation by vehicle or HNE. Lysates were immuno-blotted for levels of P-S6K 
and normalized to GAPDH (n=5, * = p <0.01 vs Veh Con, # = p < 0.05 vs U0126 
Con, $ = p < 0.05 vs Veh HNE).  
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Figure 35. Erk1/2 is not required for HNE-mediated hypertrophy in ARVMs. 
ARVMs were pretreated with DMSO or U0126 (10 µM) for 30 minutes and then 
treated with 10 µM HNE for 1 hour, after which the media was removed and 
replaced with fresh media containing [3H]-leucine and DMSO or U0126. After 24 
hours the cells were collected and assayed for incorporation of the labeled 
leucine by liquid scintillation counting (n=5, * = p < 0.05, error bars are mean ± 
standard error).  
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Figure 36. Erk1/2 activation does not alter LKB1-AMPK signaling. 
ARVMs were incubated with DMSO or U0126 (10 µM) for 30 minutes prior to 
stimulation by vehicle or HNE. The levels of P-ACC were quantified by 
densitometry and normalized to T-ACC and GAPDH (n=4, * = p <0.01 vs DMSO 
Vehicle, # = p < 0.05 vs U0126 Vehicle).  
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Having observed that Erk1/2 contributes to S6K activation, I next sought to 
elucidate the signaling intermediates that regulate HNE-mediated S6K activation. 
Due to the observation by others that hypertrophic stimuli regulate S6K activation 
via MEK-Erk1/2 and mTOR signaling, I hypothesized that hypertrophic HNE-
induced signaling changes could follow a similar mechanism. To test this 
hypothesis I used the mTOR inhibitor, Rapamycin, and with HNE treatment 
observed a complete abolishment of S6K stimulation (Figure 37). To determine if 
the inhibition of mTOR decreases S6K phosphorylation due to an effect on MEK-
Erk1/2 signaling, I examined Erk1/2 phosphorylation and found no changes with 
mTOR inhibition (Figure 38). These data suggest that mTOR is downstream from 
both the LKB1-AMPK and MEK-Erk1/2 signaling cascades and coordinates 
inputs from both cascades in order to regulate distal S6K activation with HNE 
treatment. 
 
 4.3 Discussion 
The goal of this study was to determine if HNE could directly promote 
cardiomyocyte hypertrophy, and to investigate potential signaling pathways that 
could mediate this effect. My major findings are that 1) exposure to HNE 
increases protein synthesis in cardiomyocytes, 2) HNE inhibits LKB1-AMPK 
activities and promotes hypertrophic signaling through the downstream mTOR-
P70S6K-S6K signaling cascade, 3) HNE stimulates Erk1/2 independently from  
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Figure 37. mTOR is required for HNE-mediated S6K phosphorylation. 
ARVMs were incubated with DMSO or the mTOR inhibitor Rapamycin (100 nM) 
for 30 minutes prior to stimulation by HNE (10 µM, 1 hr). Lysates were immuno-
blotted for levels of P-S6K and GAPDH (n=3-4).  
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Figure 38. Inhibition of mTOR does not alter Erk1/2 signaling. 
ARVMs were incubated with DMSO or the mTOR inhibitor Rapamycin (100 nM) 
for 30 minutes prior to stimulation by vehicle or HNE (10 µM, 1 hr). Lysates were 
immuno-blotted for levels of P-Erk, T-Erk, and GAPDH (n=3).  
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ROS or p21Ras, 4) Erk1/2 contributes to the activation of S6K with HNE 
treatment, and 5) mTOR is required for the activation of S6K by HNE.  
Previous work has demonstrated that HNE forms adducts of LKB1 (155) 
and that HNE treatment inhibits LKB1-AMPK signaling in MCF-7 cells (127) as 
well as in neonatal cardiomyocytes (63). To test if these hypertrophic signaling 
changes resulted in a cellular growth phenotype, I measured protein synthesis 
using [3H]-leucine incorporation. I observed a 24.2 ±2.4 (S.E.) % increase in 
protein synthesis with HNE treatment. In this cardiomyocyte cell system the 
effect of HNE on protein synthesis is of a smaller magnitude compared to α-AR 
stimulated protein synthesis (131). When testing the effect of HNE on protein 
synthesis, ARVMs obtained from the same cardiomyocyte isolation were 
stimulated with NE as a positive control for cell viability, and only the sets of cells 
observed to have a robust response to NE were included in the analysis (data 
not shown).  
Perhaps with an increased dose of HNE the effect on protein synthesis 
could also be increased. The low dose used in this study (10 µM) was intended 
to reduce cytotoxicity while still altering hypertrophic signaling. Because the 
cytotoxic effects of HNE may be caused by ROS production, adding an 
antioxidant may limit the cytotoxicity of HNE and allow for higher concentrations 
of HNE to be studied in this system. Whereas this is the first study to show that 
HNE can stimulate protein synthesis in cardiomyocytes, HNE can elicit mitogenic 
responses in other systems. For example, low doses of HNE (2.5 µM) increases 
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cell number and DNA synthesis rates in primary rat aortic smooth muscle cells in 
part through the activation of Erk1/2 signaling (161). 
I next sought to determine if HNE promotes hypertrophic signaling in 
ARVMs through the inhibition of LKB1-AMPK signaling. Hypertrophic stimuli are 
known to elicit differential signaling responses in adult and neonatal ventricular 
cardiomyocytes (157), which is why I decided to confirm the earlier finding in the 
adult cardiomyocyte system. In agreement with the studies conducted in the 
neonates, I observed the formation of HNE-LKB1 adducts and inhibition of LKB1 
and AMPK kinase activities. The decrease in kinase activity of these proteins 
was associated with hypertrophic signaling changes through the mTOR-P70S6K-
S6K signaling cascade, which demonstrates that the same HNE-mediated 
hypertrophic signaling changes observed in the neonatal cardiomyocyte persist 
into the adult system. 
To investigate if other hypertrophic signaling cascades were activated by 
HNE I examined the phosphorylation status of Akt, a kinase that can modulate 
4E-BP1 and S6K signaling independently of the AMPK-mTOR axis (158). HNE 
has been shown to modify and inhibit the lipid phosphatase Phosphatase and 
tensin homolog (PTEN), which functions as a negative regulator of Akt activation, 
further suggesting that Akt may be of interest (162). As was previously observed 
in neonatal cardiomyocytes, there was no change in Akt phosphorylation with 
HNE treatment. I also examined the activation of Erk1/2, as our lab has 
previously found that MAPK signaling is hypertrophic in cardiomyocytes 
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stimulated by α-adrenergic receptor agonists (131). I observed increases in 
Erk1/2 phosphorylation that could be prevented through inhibition of the 
upstream kinase MEK1/2 using the specific inhibitor U0126. Next I tested 
whether the activation of Erk1/2 occurred via the same mechanism induced by α-
AR activation in ARVMs by examining the role of ROS and p21Ras activation, 
which are required for Erk1/2 activation with α-AR stimulation. These 
experiments demonstrate that the effect of HNE on Erk1/2 is ROS independent 
and that p21Ras is not active with HNE treatment. Based on these observations 
I’ve concluded that HNE stimulates Erk1/2 through a MEK-dependent 
mechanism independent of p21Ras and ROS. Interestingly, another study has 
shown that peroxynitrite-induced Erk1/2 activation occurs independently of 
activation of the EGF receptor and p21Ras in H9C2 cardiomyocytes (163), 
suggesting an alternative mechanism by which oxidants can activate Erk1/2. 
While this work and other studies have shown that HNE stimulates Erk1/2 
activity, there are also reports that HNE can form inhibitory adducts of Erk1/2 
(62) that decrease Erk1/2 phosphorylation and downstream Elk-1 signaling (164). 
The inhibitory effect of HNE on Erk1/2 signaling occurs in the liver and primary 
hepatocytes using the same HNE dose in this study, demonstrating that 
disparate tissue-specific signaling changes can occur under otherwise 
comparable conditions. 
Having observed that HNE stimulates Erk1/2 signaling, I next investigated 
if Erk1/2 signaling contributed to hypertrophic S6K signaling and protein 
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synthesis. The inhibition of Erk1/2 using U0126 was found to decrease HNE-
stimulated S6K phosphorylation compared to cells pretreated with vehicle (Figure 
34). This observation suggests that HNE-stimulated Erk1/2 signaling contributes 
to the activation of S6K. Next I examined HNE-stimulated protein synthesis in the 
presence of U0126 using [3H]-leucine incorporation and found that Erk1/2 was 
not required for the hypertrophic effect of HNE. Whereas HNE-stimulated S6K 
phosphorylation has a nearly 3-fold increase with HNE treatment, the effect of 
HNE on protein synthesis has a much smaller fold change (see Figure 35), 
making it harder to detect an intermediate reduction in protein synthesis. In order 
to examine crosstalk between the MEK-Erk1/2 and LKB1-AMPK signaling, I also 
investigated the phosphorylation status of ACC in the presence of U0126 and 
found that inhibition of Erk1/2 had no effect on ACC with HNE treatment (Figure 
36). Others have shown that LKB1 can be phosphorylated by Erk1/2, which 
inhibits LKB1-AMPK signaling in melanoma models (160). Based on the 
observations from my work HNE-stimulated Erk1/2 activation doesn’t appear to 
contribute to the inhibition of LKB1-AMPK signaling in cardiomyocytes. 
Stimulation of hypertrophic signaling with Gq protein-couple receptor 
agonists phenylephrine (PE) and endothelin-1 in cardiomyocytes leads to 
phosphorylation of S6K, which was shown to be dependent on both MEK and 
mTOR signaling (30). Having evaluated the effect of MEK-Erk1/2 signaling on 
S6K phosphorylation, I next investigated the role of mTOR using the specific 
inhibitor Rapamycin. I observed that Rapamycin treatment completely blocked 
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both basal and HNE-stimulated S6K phosphorylation. To determine if mTOR is 
regulating Erk1/2 activation I also examined Erk1/2 phosphorylation with 
Rapamycin treatment and found no changes in Erk1/2, suggesting that mTOR is 
downstream from MEK-Erk1/2 signaling. This observation is in agreement with 
other work in cardiomyocytes examining hypertrophic signaling pathways using 
the hypertrophic stimulus PE, which found that Erk1/2 is required for the 
activation of mTOR and downstream S6K phosphorylation (165). My data 
suggests that hypertrophic signaling induced by HNE occurs via similar 
mechanisms, although LKB1-AMPK inhibition likely plays a larger role in 
regulating S6K activation. Based on the data I’ve presented herein, I conclude 
that Erk1/2 signaling contributes to S6K phosphorylation through the activation of 
mTOR. 
Another potential mediator of cellular signaling that could be targeted by 
HNE to alter hypertrophic signaling is the Sirtuin family of deacetylases. A mass 
spectrometry screen for carbonyl modifications of hepatic proteins found that 
HNE modifies and inhibits the activity of SIRT3 via specific thiol modifications 
(166). A recent study also found evidence of increased carbonylation of SIRT1 in 
aged hearts as well as HNE-SIRT1 adducts in cultured cardiomyocytes treated 
with HNE (167). Since both SIRT1 and SIRT3 activate LKB1 by deacetylation 
(111,137), it is conceivable that HNE adducts of SIRT1 and/or 3 may contribute 
to the inhibition of LKB1-AMPK signaling.  
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Based on these observations I have summarized the effects of HNE on 
LKB1-AMPK and MEK-Erk1/2 signaling in ARVMs (Figure 39). I found that HNE 
inhibits LKB1-AMPK signaling to promote hypertrophic mTOR-p70S6K-S6K 
activation and increases protein synthesis. HNE also activates MEK-Erk1/2 
signaling which likely contributes to the activation of S6K in part through mTOR. 
Finally I found that mTOR was required for the hypertrophic effect of HNE on 
S6K activation. Overall, this study provides a novel mechanism by which oxidant-
derived lipid peroxidation byproducts can promote cellular growth and may guide 
future interventions to prevent or regress pathological cardiac hypertrophy. 
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Figure 39. Diagram summarizing the effects of HNE on LKB1-AMPK and 
MEK-Erk1/2 signaling in ARVMs.  
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Chapter 5: Metabolic Myocardial Hypertrophy in Mice Fed HFHS Diet 
Involves HNE-Dependent Signaling Changes Through the LKB1-AMPK 
Signaling Axis 
 
5.1 Rationale 
Over 2/3 of Americans are overweight and 34% of adults have been 
diagnosed with metabolic syndrome, a multicomponent condition characterized 
by obesity, hypertension, elevated triglycerides, insulin resistance, and 
decreased HDL cholesterol (18,168). Metabolic syndrome increases the risk of 
cardiovascular disease, all-cause mortality, and mortality from cardiovascular 
disease, MI, and stroke (169). Obesity increases the risk of HF, and metabolic 
syndrome has been associated with increased left ventricular hypertrophy and 
diastolic dysfunction (13,170). Furthermore, patients with concentric left 
ventricular hypertrophy are more likely to develop HF with preserved ejection 
fraction (12), yet the underlying molecular mechanisms of myocardial 
hypertrophy in the setting of metabolic syndrome are unclear. 
In order to study the relationship between myocardial hypertrophy and 
metabolic syndrome, I’ve opted to use a mouse model of diet-induced obesity 
that largely recapitulates human heart failure with preserved ejection fraction. 
C57BL/6J mice fed a “western-style” HFHS diet develop myocardial hypertrophy 
and diastolic dysfunction after 8 months of HFHS feeding (43). HFHS-fed mice 
co-administered a polyphenolic antioxidant compound exhibited an amelioration 
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of myocardial hypertrophy, diastolic dysfunction, and oxidative protein 
modifications. 
Left ventricular hypertrophy has been associated with increased ROS 
production and it is well accepted that ROS have important roles in regulating 
myocardial growth via OPTMs of key signaling proteins (154). For example our 
lab has demonstrated that OPTM of p21Ras on reactive Cys residues activates 
downstream Erk1/2 signaling to promote hypertrophy in cardiomyocytes (33). 
The secondary effects of ROS caused by lipid peroxidation-derived reactive 
aldehydes is another potential mechanism by which oxidative stress can alter 
cellular signaling (55). HNE and other reactive aldehydes are increased in the 
plasma of HF patients (68) and patients with dilated cardiomyopathy exhibit 
myocardial HNE-protein modifications that were decreased after treatment with 
carvedilol, a vasodilating β-blocker with antioxidant activity (69). In a mouse 
model of systolic HF caused by cardiomyocyte-specific Gαq transgene 
expression, Gαq hearts have increased HNE levels and cardiac hypertrophy 
which were both ameliorated by transgenic expression of the antioxidant catalase 
(34).  
LKB1 is a serine/threonine kinase that phosphorylates AMPK to stimulate 
AMPK activity (99). AMPK is an evolutionarily conserved cellular energy gauge 
that simultaneously promotes energetic production and inhibits functions that 
consume energy when active. One energetically dependent phenotype regulated 
by AMPK is cellular growth, which AMPK modulates via its actions on the mTOR 
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signaling axis. AMPK indirectly inhibits mTOR through actions on the 
TSC1/TSC2 complex, which prevents both the activation of p70S6K and the 
inhibition of 4E-BP1 and thereby inhibits protein synthesis (109). In cultured 
cardiomyocytes adenoviral overexpression of LKB1 and pharmacological 
activation of AMPK both prevent cardiac hypertrophy by decreasing protein 
synthesis (113,114). Furthermore, mice with cardiac myocyte-specific deletion of 
LKB1 have left ventricular hypertrophy, severe cardiac dysfunction, and early 
mortality (115). Taken together these data suggest that the LKB1-AMPK 
signaling cascade is an inhibitory regulator of cardiomyocyte growth in the heart. 
OPTM of LKB1 by HNE inhibits the kinase function of LKB1. In MCF-7 
cells HNE adducts of LKB1 were first observed to impair downstream AMPK 
signaling (127) and in neonatal rat cardiomyocytes HNE adducts of LKB1 have 
been shown to promote hypertrophic signaling downstream of AMPK (63). Our 
lab has also observed HNE-LKB1 adducts in hearts from mice fed HFHS diet 
(43). Our lab recently identified a reactive lysine residue of LKB1 that is targeted 
by HNE adducts and mediates the inhibitory effect of HNE on LKB1 activity 
(155). Based on these observations, I now hypothesize that OPTM of LKB1 
promote myocardial hypertrophy in the HFHS-fed mouse. To test this hypothesis, 
hearts of HFHS-fed mice were examined for LKB1 and AMPK kinase activities 
and downstream signaling changes. 
I also postulated that modulating levels of HNE in the heart would impact 
signaling cascades modified by HNE exposure, namely LKB1-AMPK signaling 
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and the activation of MAPK signaling, as was observed in vitro using cardiac 
myocytes. In order to modulate HNE levels in vivo I utilized a mouse lacking the 
ALDH2 gene, a key mitochondrial enzyme involved in the detoxification of HNE 
and other aldehyde species (132). The ALDH2-KO mice are susceptible to 
myocardial ischemia/reperfusion injury, which was found to increase myocardial 
HNE levels and to suppress activation of AMPK during ischemia (171). I 
hypothesized that ALDH2-KO mice fed HFHS diet would have elevated levels of 
HNE, increased HNE-LKB1 adduct formation, and downstream AMPK-mediated 
hypertrophic signaling changes. 
 
5.2 Experiments 
 
5.2.1 HFHS feeding causes signaling changes along the LKB1-AMPK 
signaling axis that are dependent on diet duration 
In our previous studies our lab observed that hearts of mice fed HFHS diet 
are hypertrophied and have increased HNE content and HNE-LKB1 adducts 
(43). Because HNE can directly inhibit LKB1 function (155) and promote 
hypertrophic signaling changes (Chapter 4), I hypothesized that in hearts of 
HFHS-fed mice inhibitory HNE adducts of LKB1 promote hypertrophic signaling 
changes through the LKB1-AMPK-mTOR signaling cascade. In the hearts of 
mice fed HFHS diet for 8 months, LKB1 activity was decreased compared to the 
control diet (CD) group (Figure 40). I next assayed LKB1 protein content and  
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Figure 40. LKB1 activity is decreased in mice fed HFHS diet for 8 months. 
C57BL/6J mice were fed a HFHS or nutrient-matched control diet for 8 months. 
Myocardial tissue lysates were assayed for LKB1 activity using the LKBtide 
synthetic substrate in the presence of [γ-32P]-ATP (n=5-6 per group, student’s T-
test, * = p < 0.05).  
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found no difference (Figure 41), which is consistent with the hypothesis that 
inhibitory OPTM decreases LKB1 activity without a change in expression. To 
determine the functional consequences of impaired LKB1 activity I examined 
AMPK function and found no difference in kinase activity (Figure 42). Western 
blot analysis of the phosphorylation of other signaling molecules, mTOR, Akt, 
and Erk, also show no differences between control and HFHS diets (data not 
shown), suggesting that after 8 months of HFHS feeding there are no detectable 
hypertrophic signaling changes along the LKB1-AMPK-mTOR signaling axis. 
I next hypothesized that the observed myocardial hypertrophy may be 
caused by signaling changes that occur earlier in the period of the diet 
administration. After 8 months of HFHS feeding it is conceivable that myocardial 
hypertrophy is well established.  If adaptive myocardial growth has already 
reached a plateau, it might be that further pro-hypertrophic signaling changes are 
absent. In order to test if hypertrophic signaling changes occur earlier, I assessed 
myocardial lysates for changes in LKB1 activity and downstream AMPK signaling 
changes in mice fed CD or HFHS diet for 2 weeks, 1 month, 2 months, or 4 
months. Of the time points surveyed, LKB1 activity was decreased after 2 weeks 
of HFHS feeding (Figure 43) at which time there was no change in LKB1 protein 
expression (Figure 44) thus suggesting an inhibitory modification is responsible 
for the decrease in LKB1 activity. I next sought to determine if impaired LKB1 
function altered downstream signaling, and observed that in HFHS hearts AMPK 
phosphorylation at Thr-172 was increased (Figure 45) which would be expected  
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Figure 41. LKB1 expression is unchanged after 8 months of HFHS feeding. 
C57BL/6J mice were fed a HFHS or nutrient-matched control diet for 8 months. 
Proteins from myocardial tissue lysates were immuno-blotted for LKB1, 
quantified by densitometry, and normalized to GAPDH (n=3). 
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Figure 42. AMPK activity is unaltered in mice fed HFHS diet for 8 months. 
C57BL/6J mice were fed a HFHS or nutrient-matched control diet for 8 months. 
Myocardial tissue lysates were assayed for AMPK alpha2 activity using the 
SAMS synthetic substrate in the presence of [γ-32P]-ATP (n=4-6 per group).  
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Figure 43. Changes in LKB1 activity are dependent on HFHS feeding 
duration. 
C57BL/6J mice were fed a HFHS or nutrient-matched control diet for the 
indicated time points. Myocardial tissue lysates were assayed for LKB1 activity 
using the LKBtide synthetic substrate in the presence of [γ-32P]-ATP (n=4-6 per 
group, student’s T-test, * = p < 0.05).  
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Figure 44. LKB1 expression is unchanged after 2 weeks of HFHS feeding. 
C57BL/6J mice were fed a HFHS or nutrient-matched control diet for 2 weeks. 
Proteins from myocardial tissue lysates were immuno-blotted for LKB1, 
quantified by densitometry, and normalized to GAPDH (n=4). 
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Figure 45. AMPK phosphorylation is increased after 2 weeks of HFHS 
feeding. 
C57BL/6J mice were fed a HFHS or nutrient-matched control diet for 2 weeks. 
Proteins from myocardial tissue lysates were immuno-blotted for phosphorylation 
of AMPK at Thr-172, quantified by densitometry, and normalized to GAPDH 
(n=4). 
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to enhance AMPK activity. Looking further downstream at distal signaling 
changes I observed a decrease in S6K phosphorylation in HFHS-hearts (Figure 
46) which is consistent with increased AMPK activity. I also examined Erk1/2 and 
found no change in phosphorylation with HFHS feeding (Figure 47). The changes 
in LKB1 activity and other signaling proteins observed in the HFHS-fed hearts at 
various time points have been summarized for an easier comparison (Table 2).  
 
5.2.2 ALDH2-KO mice fed HFHS have increased myocardial 
hypertrophy 
Having observed that there are alterations in LKB1 activity in HFHS-fed 
mice hearts, I next wanted to test the hypothesis that increasing HNE levels by 
impairing HNE detoxification could further impair LKB1 to promote hypertrophic 
signaling changes. Both WT and ALDH2-KO mice were fed HFHS or CD for 4 
months and evaluated for indices of myocardial hypertrophy and dysfunction by 
echocardiography. Myocardial lysates from these mice were subjected to 
immuno-blot analysis and kinase assays to study cellular signaling changes. 
At baseline, ALDH2-KO mice have no cardiovascular phenotype as 
observed by echocardiography (data not shown). Specifically, there are no 
changes in total wall thickness, fractional shortening, or in measurements of  
passive ventricular filling (Em, one indicator of diastolic function). After 4 months 
of HFHS feeding the ALDH2-KO mice exhibit increased myocardial wall 
thickness compared to WT mice fed HFHS diet (Figure 48). Measurements of  
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Figure 46. S6K phosphorylation is decreased after 2 weeks of HFHS 
feeding. 
C57BL/6J mice were fed a HFHS or nutrient-matched control diet for 2 weeks. 
Proteins from myocardial tissue lysates were immuno-blotted for phosphorylation 
of S6K, quantified by densitometry, and normalized to GAPDH (n=4). 
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Figure 47. Erk phosphorylation is unchanged after 2 weeks of HFHS 
feeding. 
C57BL/6J mice were fed a HFHS or nutrient-matched control diet for 2 weeks. 
Proteins from myocardial tissue lysates were immuno-blotted for levels of 
phosphorylated Erk and normalized to levels of total Erk and GAPDH (n=4). 
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 2 weeks 1 month 2 months 4 months 8 months 
LKB1 Activity Down - - - Down 
LKB1 Expression - - - - - 
AMPK 
Phosphorylation at 
Thr-172 
Up - - - - 
ACC  
Phosphorylation at 
Ser-79 
- - - -  
  
 
 
Table 2. Myocardial protein function and signaling changes that occur as a 
result of diet duration in HFHS-fed mice. In mice fed HFHS diet for 2 weeks, 1 
month, 2 months, 4 months, and 8 months or control diet the following 
parameters were assessed: LKB1 activity by kinase activity assay and LKB1 
expression, AMPK phosphorylation at Thr-172, and ACC phosphorylation at Ser-
79 were all assessed by western blotting and normalized to a loading control. 
The (-) marks indicates no change in HFHS-fed mice compared to control diet 
feeding. 
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Figure 48. ALDH2-KO mice fed HFHS have increased myocardial wall 
thickness. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet for 4 
months and evaluated for changes in myocardial wall thickness by 
echocardiography (n=5-6 per group, * = p < 0.05 vs WT Chow, † = p < 0.05 vs 
WT HFHS). Data courtesy of Fuzhong Qin.  
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diastolic function indicate a slight impairment of ventricular relaxation in the 
ALDH2-KO mice fed HFHS compared to WT HFHS mice, however this difference 
is not statistically significant due to the low number of animals per group (Figure 
49). Both genotypes have preserved systolic function, which suggests that loss of 
ALDH2 function is not causing severe cardiac dysfunction with nutrient stress 
(Figure 50). After 4 months of HFHS feeding, ALDH2-KO mice had comparable 
weight gain with both diets (Figure 51). The LV mass of ALDH2-KO HFHS mice 
was greater than the LV mass of WT mice fed HFHS (Figure 52), which is 
consistent with the echocardiography observations. Based on these data I 
conclude that loss of ALDH2 function promotes increases myocardial 
hypertrophy and potentially impairs diastolic dysfunction in mice administered a 
western-style diet. 
 
5.2.3 ALDH2-KO mice fed HFHS have increased LKB1 activity and no 
changes in downstream AMPK phosphorylation 
Thus far I’ve observed that after 8 months of HFHS feeding there is 
decreased LKB1 activity that is associated with increased HNE levels. ALDH2-
KO mice fed HFHS for 4 months have increased myocardial hypertrophy. I next 
set out to investigate the mechanism of increased hypertrophy in ALDH2-KO 
hearts by examining hypertrophic signaling cascades in myocardial tissue 
lysates. I hypothesized that elevated HNE levels in ALDH2-KO HFHS hearts  
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Figure 49. Measures of left ventricular relaxation in ALDH2-KO mice fed 
HFHS diet. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet for 4 
months and evaluated for changes in Em by tissue doppler imaging (n=2-3 per 
group). Data courtesy of Fuzhong Qin.  
 113 
 
 
 
 
Figure 50. There is no change in systolic function of ALDH2-KO mice fed 
HFHS diet. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet for 4 
months and evaluated for changes in fractional shortening by echocardiography 
(n=5-6 per group). Data courtesy of Fuzhong Qin.  
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Figure 51. Body weights of WT and ALDH2-KO mice fed HFHS diet for 4 
months. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet (CD) 
for 4 months and evaluated for changes in total body weight at the end of the 
study (n=5-6 per group, ** = p < 0.01).  
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Figure 52. ALDH2-KO mice fed HFHS diet have increased LV mass 
compared to WT HFHS mice. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet (CD) 
for 4 months. The dry weight of the left ventricle (LV) was normalized to tibia 
length. For both WT and ALDH2-KO genotypes the ratio of LV mass to tibia 
length was normalized to the CD group (n=5-6 per group, ** = p < 0.01).  
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could be exacerbating the decline of LKB1 function, thereby promoting 
myocardial hypertrophy in these mice.  
After 4 months of HFHS feeding I observed increased LKB1 activity in 
ALDH2-KO mice (Figure 53). To investigate if the altered LKB1 activity was 
caused by increased LKB1 protein levels in response to HFHS feeding in 
ALDH2-KO mice, I examined LKB1 expression, yet found no change in protein 
levels (Figure 54). I next looked downstream at AMPK phosphorylation of Thr-
172 and found no change in ALDH2-KO HFHS hearts (Figure 55). Finally, I 
examined Erk1/2 activation and found no difference in Erk1/2 phosphorylation in 
ALDH2-KO HFHS hearts (Figure 56). 
Based on these findings, the inhibition of LKB1 isn’t promoting 
downstream hypertrophic signaling changes in HFHS-fed ALDH2-KO hearts. 
Furthermore the observation that LKB1 activity is increased in ALDH2-KO HFHS 
hearts suggests that increased LKB1 function is not sufficient to prevent 
myocardial hypertrophy in mice with metabolic heart disease. Interestingly, I have 
again observed a non-linear relationship between LKB1-AMPK activities in the 
HFHS-fed hearts, as I would have expected increased LKB1 activity to augment 
the phosphorylation of AMPK. The observation that LKB1 activity is increased in 
ALDH2-KO HFHS hearts without any change in LKB1 protein expression 
suggests a post-translational modification may be responsible for increased 
LKB1 function. 
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Figure 53. ALDH2-KO mice fed HFHS have increased LKB1 activity. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet (CD) 
for 4 months. Myocardial tissue lysates were assayed for LKB1 activity using the 
LKBtide synthetic substrate in the presence of [γ-32P]-ATP (n=5-6 per group, ** = 
p < 0.01).  
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Figure 54. LKB1 expression is unchanged in ALD2-KO mice fed HFHS diet. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet (CD) 
for 4 months. Proteins from myocardial tissue lysates were immuno-blotted for 
LKB1, quantified by densitometry, and normalized to GAPDH (n=5-6). 
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Figure 55. AMPK phosphorylation is unchanged in ALDH2-KO mice fed 
HFHS diet. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet (CD) 
for 4 months. Proteins from myocardial tissue lysates were immuno-blotted for 
phosphorylation of AMPK at Thr-172, quantified by densitometry, and normalized 
to GAPDH (n=5-6). 
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Figure 56. Erk phosphorylation is unchanged in ALDH2-KO mice fed HFHS 
diet. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet (CD) 
for 4 months. Proteins from myocardial tissue lysates were immuno-blotted for 
levels of phosphorylated Erk and normalized to levels of total Erk and GAPDH 
(n=5-6). 
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5.2.4 ALDH2-KO mice fed HFHS have mitochondrial dysfunction and 
increased mitochondrial-derived ROS 
ALDH2 is a mitochondrial protein that confers cardio-protection in part 
through the detoxification of reactive aldehydes (172). Because ALDH2 is 
localized to the mitochondrion, I hypothesized that ALDH2-KO mice fed HFHS 
would have impaired mitochondrial function and elevated levels of 
mitochondrion-derived ROS. In these mice excess mitochondrial ROS may also 
be contributing to the observed myocardial hypertrophy. In order to determine if 
mitochondrial dysfunction contributes to the myocardial phenotype of ALDH2-KO 
mice fed HFHS diet, cardiac mitochondria were isolated and assayed for 
changes in oxygen consumption, ATP synthesis rates, and hydrogen peroxide 
(H2O2) production. In order to determine the contribution of the individual 
mitochondrial complexes, these assays were conducted in the presence of 
specific substrates to Complex I and Complex II. For measurements of Complex I 
mitochondria were supplied with pyruvate and malate. For Complex II 
measurements the substrate succinate was provided in addition to the Complex I 
inhibitor rotenone. 
Isolated cardiac mitochondria from ALDH2-KO mice had a trend towards 
decreased Complex I maximal respiration that was unaffected by HFHS feeding 
(Figure 57). To evaluate the significance of any mitochondrial Complex I defects 
ATP synthesis rates were examined. Isolated mitochondria from ALDH2-KO 
hearts from mice fed either diet were found to have markedly depressed ATP  
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Figure 57. Complex I maximal oxygen consumption in ALDH2-KO hearts. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet (CD) 
for 4 months. Isolated cardiac mitochondria were assessed for maximal ADP-
stimulated State III oxygen uptake in the presence of Complex I substrates 
pyruvate and malate (n=3-5). Data courtesy of Aly Elezaby. 
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synthesis rates compared to the WT mice (Figure 58). To determine if impaired 
mitochondrial ATP synthesis resulted in the production of ROS, H2O2 production 
in isolated mitochondria was measured. ALDH2-KO mice had a higher baseline 
H2O2 production that was not further increased by HFHS feeding (Figure 59). 
This data suggests Complex I-derived mitochondrial dysfunction doesn’t result in 
increased mitochondrial ROS production.  
In regards to mitochondrial Complex II-derived function, maximal rates of 
respiration were decreased in isolated mitochondria from the ALDH2-KO mice 
fed either diet (Figure 60). This suggests a defect in the electron transport chain 
at Complex II when reverse electron flow is prevented with rotenone. Rates of 
ATP synthesis were also decreased in ALDH2-KO mice, with no further 
alterations with HFHS feeding (Figure 61), suggesting impaired mitochondrial 
oxygen-linked ATP synthesis. Cardiac mitochondrial H2O2 production was also 
observed to be markedly increased in ALDH2-KO mice fed HFHS, (Figure 62) 
suggesting that impaired mitochondrial function may promote additional ROS 
leak from mitochondria in these mice. 
 
5.3 Discussion 
In this study I’ve made the following observations: 1) LKB1 function is 
impaired with either 2 weeks or 8 months of HFHS feeding and AMPK activity or 
phosphorylation is unchanged, 2) ALDH2-KO mice have increased myocardial 
hypertrophy when fed HFHS diet for 4 months, 3) ALDH2-KO HFHS mice have  
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Figure 58. ALDH2-KO mice have decreased ATP synthesis rates with 
Complex I substrates. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet (CD) 
for 4 months. Isolated cardiac mitochondria were assessed for changes in ATP 
synthesis rates in the presence of Complex I substrates pyruvate and malate 
(n=3-5, * = p < 0.05 vs WT CD, # = p < 0.05 vs WT HFHS). Data courtesy of 
Aaron Sverdlov. 
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Figure 59. Mitochondrial-derived ROS production with Complex I 
substrates is increased in ALDH2-KO mice. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet (CD) 
for 4 months. Isolated cardiac mitochondria were assessed for hydrogen 
peroxide production using Amplex Red in the presence of Complex I substrates 
pyruvate and malate (n=3-5, * = p < 0.05 vs WT CD). Data courtesy of Aaron 
Sverdlov. 
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Figure 60. ALDH2-KO mice have decreased Complex II maximal oxygen 
consumption. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet (CD) 
for 4 months. Isolated cardiac mitochondria were assessed for maximal ADP-
stimulated State III oxygen uptake in the presence of Complex II substrate 
succinate and the Complex I inhibitor rotenone (n=3-5, * = p < 0.05). Data 
courtesy of Aly Elezaby. 
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Figure 61. ALDH2-KO mice have decreased ATP synthesis rates with 
Complex II substrates. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet (CD) 
for 4 months. Isolated cardiac mitochondria were assessed for changes in ATP 
synthesis rates in the presence of Complex II substrate succinate and the 
Complex I inhibitor rotenone (n=6, ** = p < 0.01 vs WT CD, # = p < 0.05 vs WT 
HFHS). Data courtesy of Aaron Sverdlov. 
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Figure 62. ALDH2-KO mice fed HFHS have increased mitochondrial ROS 
production with Complex II substrates. 
WT and ALDH2-KO mice were fed a HFHS or nutrient-matched control diet (CD) 
for 4 months. Isolated cardiac mitochondria were assessed for hydrogen 
peroxide production using Amplex Red in the presence of Complex II substrate 
succinate and the Complex I inhibitor rotenone (n=3-5, * = p < 0.05 vs WT HFHS, 
# = p <0.05 vs ALDH2-KO CD). Data courtesy of Aaron Sverdlov. 
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increased myocardial LKB1 activity with change in AMPK phosphorylation, and 
4) ALDH2-KO mice have markedly impaired ATP synthesis rates and decreased 
maximal respiration. 
After 8 months of HFHS feeding I observed decreased LKB1 activity yet 
no changes in AMPK function or in downstream hypertrophic signaling cascades. 
In a prior study our lab observed HNE-LKB1 adducts in hearts of HFHS-fed mice 
(43), and because HNE is an inhibitory modification of LKB1 (155), these results 
suggest that LKB1 is inhibited by HNE. With short term HFHS feeding (2 weeks) 
there is decreased LKB1 activity, yet I observed increased AMPK 
phosphorylation, and decreased S6K phosphorylation. The non-linear 
relationship between LKB1 and AMPK function in HFHS mice suggests that 
AMPK is being regulated via an LKB1-independent process. The fact that short 
term HFHS feeding (2 weeks) and long term (8 months) leads to decreased 
LKB1 function but the in between time points (1, 2, and 4 months) have no effect 
on LKB1 activity was unexpected. This may be due to two separate processes 
that differentially regulate LKB1 function. For example the effect of short term 
HFHS feeding on LKB1 function may be the result of metabolic adaptations to 
increased lipid and sucrose, and it may occur as a mechanism to decrease 
AMPK function in the setting of nutrient excess. With 8 months of feeding, LKB1 
function is likely inhibited by HNE, due to the observation of HNE-LKB1 adducts 
at this time point. 
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This work is the first to report an effect of nutrient excess on the activity of 
LKB1 in the heart. Previous reports on LKB1 function in the heart have 
demonstrated decreased LKB1 function in the spontaneously hypertensive rat 
and decreased LKB1 protein in a transgenic mouse overexpressing the 
calcineurin protein (63,114). Cardiomyocyte specific knockout of LKB1 causes 
cardiac hypertrophy and dysfunction (115) and demonstrates that myocardial 
LKB1 inhibition is sufficient to promote hypertrophy. A number of studies have 
reported that high fat diet decreases AMPK activity in the hearts of mice 
(173,174) and rats (175). Diabetic leptin-deficient (ob/ob) mice have decreased 
AMPK phosphorylation in the heart (176). Infiltration of inflammatory 
macrophages in the heart caused by nutrient excess may also impair AMPK 
activation. Mice fed a high fat diet for 6 weeks had increased macrophage 
infiltration in the heart and decreased AMPK activation. Infusion of interleukin-6 
decreased AMPK phosphorylation and may be a mediator of inflammation-
induced AMPK inactivation (177). AMPKα2 kinase-deficient mice fed a high fat 
diet for 20 weeks exhibited increased myocardial hypertrophy and elevated 
hypertrophic mTOR signaling, suggesting that AMPK is involved in regulating 
growth under conditions of nutrient excess (178). It should be noted that other 
reports indicate AMPK is not affected by high fat feeding in rats (179) and high 
fat feeding for 8 weeks increases AMPK phosphorylation in mice (180).  
Together these studies indicate that the time point for measuring AMPK 
activation can impact the results. It is also conceivable that subtle differences in 
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each high fat diet such as the percentage of fat/carbohydrate/protein, the source 
of fat, and the sugar content could confound the result of high fat feeding in 
rodents. Finally, the effect of various diets on cardiac function should be carefully 
considered when evaluating myocardial AMPK activation. For example, high fat 
feeding decreases AMPK phosphorylation in the heart but this was accompanied 
by systolic dysfunction (178). Considering the HFHS-fed mouse used in this 
study has no systolic dysfunction with up to 8 months of HFHS feeding, the 
differences in AMPK activation may reflect the differential myocardial function. 
These results lead me to conclude that while LKB1 is inhibited with HFHS 
feeding, presumably due to oxidative modification by HNE, the resulting 
decrease in LKB1 function is not sufficient to promote hypertrophic signaling 
through the AMPK signaling cascade at the time points evaluated. It is possible 
that during conditions of nutrient excess in the heart AMPK function is being 
regulated through a non-LKB1 dependent mechanism. With HFHS feeding our 
lab has observed a variety of cardiac mitochondrial abnormalities (data not 
shown) that may result in impaired energetic balance. Allosteric activation of 
AMPK with the low energy substrate AMP (181) is a potential mechanism by 
which AMPK can be activated in the setting of decreased LKB1 function. Other 
groups have reported that cardiovascular mitochondria from animal models of 
obesity and diabetes have impaired energetics. Cardiac mitochondria isolated 
from both ob/ob and leptin receptor deficient (db/db) mice have decreased ATP 
synthesis rates and lower cardiac efficiency in the presence of fatty acid 
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substrate (24,182). Mice with a genetic ablation of uncoupling protein in brown 
adipose tissue are obese and insulin-resistant (183,184). In these transgenic 
mice cardiovascular mitochondria have decreased ATP synthesis rates and 
lower cardiac efficiency (185). Cardiac mitochondria from HFHS-fed mice have 
impaired myocardial ATP synthesis rates after 4 months of HFHS feeding (Figure 
61). This suggests overall energetic imbalance in these hearts may lead to 
allosteric activation of AMPK. Future studies evaluating ATP content as well as 
levels of the low energy substrates ADP and AMP will provide more information 
regarding the net energetic balance in HFHS hearts. 
Aside from LKB1, both CamKK and TGF-β-activated kinase 1 (TAK1) can 
phosphorylate and activate AMPK at Thr-172 (186-188). It is possible that 
increased activity of either of these kinases could compensate for LKB1 inhibition 
to maintain AMPK phosphorylation and activity. Whether these proteins are 
activated in the HFHS-fed heart and contribute to AMPK phosphorylation is a 
future direction to investigate. Another potential mediator of AMPK activation is 
oxidative stress. ROS are well known for their actions on the LKB1-AMPK 
pathway (189) and may be contributing to the activation of AMPK concurrently 
with HNE-mediated LKB1 inactivation. 
 In order to modulate HNE levels in the heart and test the effect of 
increased HNE on hypertrophic signaling cascades I utilized ALDH2-KO mice fed 
HFHS diet. After 4 months of HFHS diet hearts of ALDH2-KO mice exhibit 
increased myocardial hypertrophy, potentially impaired ventricular relaxation, and 
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no change in systolic function. I hypothesized that increased HNE content in 
these hearts would impair LKB1 activity and promote increased myocardial 
hypertrophy. ALDH2-KO mice fed HFHS diet have increased LKB1 activity and 
no change in the phosphorylation of both AMPK and Erk1/2. These data suggest 
that loss of ALDH2 promotes increased myocardial hypertrophy through an 
LKB1-AMPK independent mechanism. 
 One potential mediator of increased myocardial hypertrophy in ALDH2-KO 
mice fed HFHS diet is hypertension. WT HFHS-fed mice develop aortic stiffening 
within 1 month, which precedes the development of systolic hypertension (190). 
Aortic rings from ALDH2-KO mice have a blunted response to acetylcholine-
induced endothelial relaxation, possibly related to an impairment of aortic 
distensibility in these mice under basal conditions (191). Based on these data it is 
possible that ALDH2-KO mice fed HFHS diet could have accelerated aortic 
stiffening and increased systemic blood pressure that would promote myocardial 
hypertrophy independent of HNE-dependent signaling changes. 
 In hearts of ALDH2-KO mice fed HFHS, LKB1 function is increased with 
no change in LKB1 protein expression, which suggests a post-translational 
modification of LKB1 is responsible for the change in activity. Post-translational 
modification of LKB1 by phosphorylation at Ser-307 and Ser-431 are both 
reported to increase LKB1 function (120,122). While a number of labs have used 
phosphorylation as a surrogate for LKB1 function, our lab has observed that 
commercial antibodies targeting phosphorylation at Ser-431 are immuno-reactive 
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in mouse hearts genetically lacking LKB1 (data not shown). Attempts at using 
commercial antibodies directed against phosphorylation at LKB1 Ser-307 have 
not yielded any immuno-reactive bands by western blotting. Using an antibody 
directed against the Ser/Thr phosphorylation motif could be used to detect 
changes in phosphorylation on immuno-precipitated LKB1 protein. 
 It should be noted that the LKB1 activity assay used in this study 
examines the ability of immuno-precipitated LKB1 protein to phosphorylate and 
activate a synthetic substrate. While this approach is suitable for studying the 
effect of stable post-translational modifications on LKB1 function, it may not 
entirely reflect the status of LKB1 in an intact cell. Activity of LKB1 is regulated by 
both localization and interaction with the adaptors STRAD and MO25 to form a 
heterotrimeric complex (110). In this activity assay the contribution of both LKB1 
localization and STRAD-MO25 protein interactions may not be accurately 
represented. Since myocardial whole cell lysates contain protein from both 
nuclear and cytosolic components, the activity assay negates any effects of 
LKB1 regulation by localization. Similarly, differential localization of STRAD and 
MO25 is eliminated in the cellular lysis, and it is conceivable that these proteins 
could interact with LKB1 to form an active complex following lysis of the 
subcellular compartments. In order to overcome these shortcomings, subcellular 
fractionation of cytosolic and nuclear compartments could be conducted in order 
to study the activity of LKB1 in different cellular compartments. 
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 Mitochondria isolated from hearts of ALDH2-KO mice fed HFHS diet have 
increased ROS production and impaired ATP synthesis in the presence of 
Complex I substrates. Complex II stimulated maximal oxygen consumption is 
decreased, ROS production is increased, and ATP synthesis rates are 
decreased. Based on these observations I’ve concluded that ALDH2-KO mice 
have mitochondrial abnormalities that may impair overall energetic balance. 
These data confirm previous reports in which cardiac mitochondria isolated from 
ALDH2-KO mice show increased levels of mitochondrial superoxide formation 
using HPLC-based dihydroethidium detection (191). 
Based on the role of ALDH2 in detoxifying reactive aldehydes it is 
conceivable that oxidative modification by HNE or another reactive aldehyde is 
altering Complex I function. HNE modifies mitochondrial proteins including 
NADP+-isocitrate dehydrogenase (192) and the Complex IV protein cytochrome 
C oxidase (61). Furthermore, a mass spectrometry analysis of mitochondrial 
complex proteins has identified a number of HNE modifications on Complex I 
proteins (193). Work in our lab is being conducted to address the activity of 
Complexes I and II in ALDH2-KO mice, and to determine if oxidative 
modifications on electron transport chain complex proteins are involved in the 
observed mitochondrial abnormalities. 
Based on the results of these mitochondrial studies, I’ve concluded that 
ALDH2-KO mice fed HFHS diet have mitochondrial dysfunction and increased 
levels of mitochondrial-derived ROS. The increased levels of mitochondrial ROS 
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may be contributing to the observed hypertrophy in the ALDH2-KO HFHS-fed 
mice. When comparing the mitochondrial phenotype of the ALDH2-KO mice, 
there was cardiac mitochondrial dysfunction regardless of diet status. The only 
significantly different mitochondrial phenotype is the increased levels of Complex 
II-derived mitochondrial ROS observed with HFHS feeding. The fact that ALDH2-
KO mice fed control diet have no myocardial changes yet have persistent 
mitochondrial dysfunction further implicates the role of ROS in promoting 
myocardial hypertrophy in the ALDH2-KO mice fed HFHS diet. It is also 
conceivable that ALDH2-KO mice have compensatory upregulation of antioxidant 
enzymes, such as the cytosolic isoform of ALDH, ALDH1. Increased ALDH1 
activity may lead to decreased cytosolic HNE levels. Considering LKB1 is a 
nuclear/cytosolic protein, it is possible that increased ALDH1 function could 
prevent the inhibition of LKB1 by HNE, and could explain the unexpected 
increased in LKB1 function with HFHS feeding in these mice. 
The presence of HNE in myocardial tissue sections from ALDH2-KO mice 
can be determined using immunohistochemistry for the HNE modification. There 
is currently no data to support that HNE is modifying LKB1 protein in hearts of 
ALDH2-KO mice. Technical limitations have prevented me from obtaining reliable 
data on the status of HNE-LKB1 adducts in hearts. A mass spectrometry based 
approach to evaluate oxidatively modified proteins is being considered as a more 
comprehensive way to evaluate HNE adduct formation in hearts of HFHS-fed 
animals. 
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In other rodent models of obesity and diabetes, decreased cardiac ALDH2 
protein and activity was associated with elevated levels of lipid peroxidation 
byproducts and ROS (194,195). In myocardial lysates ALDH2 protein content 
was unchanged after 4 months of HFHS feeding (data not shown). Whether there 
is a decrease in ALDH2 activity in hearts of HFHS-fed mice is currently unknown. 
At high levels HNE inhibits ALDH2 (196), and since HNE levels are elevated in 
HFHS hearts it is conceivable that ALDH2 function could be decreased, thus 
producing more reactive aldehyde species. 
 Overall this study provides novel insights into the role of LKB1-AMPK 
signaling in diet-induced cardiac hypertrophy. These results demonstrate that 
nutrient excess increases HNE adduct formation and inhibits LKB1 activity. The 
net effect on AMPK activity appears to be independent of LKB1. HFHS feeding in 
ALDH2-KO mice increases myocardial hypertrophy, causes mitochondrial 
dysfunction, and increases mitochondrial production of oxidants. In summary this 
study provides evidence that oxidative modification of the LKB1 protein occurs in 
a mouse model of metabolic heart disease and is associated with decreased 
LKB1 function.  
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Chapter 6: Summary and Conclusion 
  The main goal of this study was to investigate mechanisms of cardiac 
hypertrophy induced by lipid peroxide byproducts in the setting of metabolic heart 
disease. Specifically I sought to understand the mechanisms by which the lipid 
peroxidation byproduct HNE can promote hypertrophy, and investigated the 
inhibitory effect of HNE on the tumor suppressor protein LKB1. In HF ROS are 
elevated and can directly promote pathophysiological processes such as cardiac 
hypertrophy, yet the relative contribution of ROS-induced lipid peroxide 
byproducts remains unclear. This study has successfully investigated the 
mechanisms by which HNE can alter LKB1 protein function to promote 
hypertrophy in the heart. 
In the first aim, I sought to determine the biochemical mechanism of LKB1 
inhibition by HNE. Using HEK293T cells to express GST-tagged LKB1 and the 
adaptor proteins STRAD and MO25, I have shown that HNE forms covalent 
adducts on LKB1 that inhibit protein function. HNE treatment doesn’t alter LKB1 
localization or the formation of the LKB1-STRAD-MO25 heterotrimeric protein 
complex, but rather inhibits LKB1 by oxidative modification. Mutation of LKB1 
Lys-96 or Lys-97 to Arg decreases HNE adduct formation, and the mutation of 
both residues (K96R/K97R) further decreases HNE adduct formation on LKB1. 
By analyzing LKB1 activity of the different LKB1 Lys to Arg mutated constructs, I 
observed that Lys-96 is not the functional target of HNE adduction. Mutation of 
LKB1 Lys-97 is sufficient to prevent the inhibitory effect of HNE on LKB1 
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function, indicating Lys-97 is the functional site modified by HNE adduction. 
These data demonstrate that HNE modification of LKB1 inhibits LKB1 function 
and suggests a potential mechanism whereby anti-hypertrophic LKB1 signaling 
could be inhibited in the context of increased oxidative stress. 
In the second aim, I examined the effects of HNE on hypertrophic 
signaling using cultured cardiomyocytes. I found that pathophysiologically 
relevant doses of HNE (10 µM, 1 hr) were sufficient to induce HNE-LKB1 
adducts, inhibit LKB1-AMPK signaling, and promote hypertrophy through the 
mTOR-p70S6K-S6K signaling axis. Consistent with these hypertrophic signaling 
changes, HNE exposure increased protein synthesis in ARVMs. In addition to 
inhibiting LKB1-AMPK signaling, HNE also increased Erk1/2 phosphorylation, 
which was found to be independent of ROS formation or p21Ras activation. 
While HNE-stimulated Erk1/2 was not required for HNE-stimulated hypertrophy, I 
did observe that Erk1/2 contributed to activation of hypertrophic S6K signaling. 
Finally, the effects of HNE on S6K phosphorylation required the action of mTOR, 
which acts as a hub to integrate HNE-dependent signaling through the LKB1-
AMPK and MEK-Erk1/2 signaling cascades. The data in this aim demonstrate 
that HNE added exogenously to cultured cardiomyocytes can promote 
hypertrophy through changes along the LKB1-AMPK signaling axis. 
In the third aim, I investigated the function of LKB1 and AMPK in the 
setting of metabolic heart disease and elevated levels of HNE caused by deletion 
of the ALDH2 gene. In hearts of mice fed HFHS diet I found that short term (2 
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wks) and long term (8 months) HFHS feeding decreased LKB1 activity and was 
associated with HNE-LKB1 adduct formation (8 months). These changes in LKB1 
function were not linearly related to AMPK phosphorylation or activity, indicating 
that an LKB1-independent process is affecting AMPK in this model. Furthermore, 
hypertrophic signaling changes (mTOR, Erk1/2) were not activated, suggesting 
that alterations in LKB1 function were not promoting hypertrophic signaling at the 
time points studied.  
In order to increase the amount of HNE in the heart and further examine 
HNE-dependent hypertrophic signaling cascades I utilized ALDH2-KO mice, 
which lack an enzyme that detoxifies reactive aldehydes such as HNE. ALDH2-
KO mice fed HFHS diet for 4 months had increased myocardial hypertrophy and 
alterations in ventricular relaxation. Contrary to what I expected, LKB1 activity in 
the hearts of these mice was increased, and not associated with downstream 
signaling changes that would promote hypertrophy or explain the increased 
hypertrophy that was observed. These results suggest LKB1 activity is increased 
by a post-translational modification, and that AMPK function is regulated 
independently of LKB1 in these mice. Lastly in ALDH2-KO mice fed HFHS 
cardiac mitochondria had decreased oxygen consumption rates and impaired 
ATP synthesis, which was associated with increased mitochondrial ROS 
production. 
Together these data indicate that HNE is sufficient to increase myocardial 
hypertrophy in cultured cardiomyocytes through the inhibition of LKB1. A major 
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limitation of this study has been the inability to carry the mechanism identified in 
HEK293T cells to the cardiomyocyte cell system in order to test if HNE-
stimulated protein synthesis can be prevented by mutation of LKB1 at Lys-97. In 
this regard, the expression of LKB1 by adenovirus in primary cardiomyocytes did 
not significantly increase LKB1 protein expression. Furthermore phosphorylation 
of AMPK was not increased with LKB1 overexpression, suggesting that LKB1 
was not expressed at high enough levels to increase the activation of AMPK. 
Another limitation of this work has been the observation that in a mouse 
model with elevated HNE levels (mice fed HFHS diet for 8 months) decreased 
LKB1 activity appears unrelated to AMPK activity or downstream hypertrophic 
signaling changes. Whereas in a cell culture model signaling cascades may 
appear linear, the in vivo regulation of energetically sensitive proteins (such as 
AMPK and mTOR) in the setting of nutrient excess is likely much more 
complicated. 
Regardless of these limitations, the sum of these data successfully 
indicates that HNE can directly promote cardiac hypertrophy and does so in part 
through inhibition of the LKB1-AMPK signaling cascade. This study has identified 
a novel mechanism by which HNE inhibits the function of LKB1 by covalent 
adduct formation. The observation that HNE stimulates cardiac hypertrophy and 
activates Erk1/2 signaling is also novel. The impairment of mitochondrial function 
in ALDH2-KO mice and the potential for OPTMs of mitochondrial proteins to alter 
mitochondrial activity in these mice is an avenue of future work. Together these 
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data provide evidence that free radical mediated lipid peroxidation byproducts 
are sufficient to promote cellular growth through distinct signaling cascades.  
Examining this work from a translational medicine perspective, 
therapeutics aimed at decreasing HNE content or at alleviating LKB1 inhibition 
may prove beneficial in attenuating cardiac hypertrophy. Decreasing HNE levels 
could be achieved by increasing HNE detoxification. Currently a small molecule 
activator of ALDH2, ALDH2 activator-1 (Alda-1), has been shown to enhance 
ALDH2 activity and accelerate rates of HNE detoxification (172). Preventing the 
effects of oxidative stress on LKB1 inhibition could also be a therapeutic 
mechanism to decrease cardiac hypertrophy. While no targeted small molecule 
activators of LKB1 currently exist, it is conceivable that activation of the 
downstream target AMPK could bypass any inhibitory effect on LKB1. Currently 
the drug Metformin is widely used in the treatment of diabetes and is thought to 
exert its beneficial effects in part through AMPK activation. My work suggests 
that these two drugs (Alda-1 and Metformin) could be utilized to decrease cardiac 
hypertrophy in the context of obesity and HF. 
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